

1 **Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving**
2 **proteostasis imbalance and ciliogenesis defects**

3
4 Holly Y. Chen^{1†}, Manju Swaroop^{2‡}, Samantha Papat^{1‡}, Anupam K. Mondal^{1‡}, Gregory J. Tawa²,
5 Florian Regent¹, Hiroko Shimada^{1§}, Kunio Nagashima³, Natalia de Val³, Samuel G. Jacobson⁴,
6 Wei Zheng², Anand Swaroop^{1*}

7
8 ¹Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National
9 Institutes of Health; Bethesda, MD 20815, USA

10 ²National Therapeutics for Rare and Neglected Diseases, National Center for Advancing
11 Translational Sciences, National Institutes of Health; Rockville, MD 20850, USA

12 ³Electron Microscopy Laboratory, National Cancer Institute, Center for Cancer Research, Leidos
13 Biomedical Research, Frederick National Laboratory; Frederick, MD 21701, USA

14 ⁴Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University
15 of Pennsylvania; Philadelphia, PA 19104, USA

16
17 [†]Current address: Department of Cell, Developmental and Integrative Biology, University of
18 Alabama at Birmingham; Birmingham, AL 35233, USA

19 [§] Current address: Department of Physiology, Keio University School of Medicine; Tokyo 160-
20 8582, Japan

21
22 [‡]These authors contributed equally

23 ^{*}Corresponding author. E-mail: swaroopa@nei.nih.gov

28 **Abstract**

29 Ciliopathies manifest from sensory abnormalities to syndromic disorders with multiorgan
30 pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a
31 major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain
32 photoreceptor survival, we performed an unbiased, high-throughput screening of over 6,000
33 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem
34 cells (iPSC) of *rd16* mouse, which is a model of Leber congenital amaurosis (LCA)¹⁰ caused by
35 mutations in the cilia-centrosomal gene *CEP290*. We identified five non-toxic positive hits,
36 including the lead molecule reserpine, which improved photoreceptor survival in *rd16* organoids.
37 Reserpine also maintained photoreceptors in retinal organoids derived from induced pluripotent
38 stem cells of *LCA10* patients and in *rd16* mouse retina *in vivo*. Reserpine-treated patient
39 organoids revealed modulation of signaling pathways related to cell survival/death, metabolism,
40 and proteostasis. Further investigation uncovered misregulation of autophagy associated with
41 compromised primary cilium biogenesis in patient organoids and *rd16* mouse retina. Reserpine
42 partially restored the balance between autophagy and the ubiquitin-proteasome system, at least in
43 part by increasing the cargo adaptor p62 and improving primary cilium assembly. Our study
44 identifies effective drug candidates in preclinical studies of *CEP290* retinal ciliopathies through
45 cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis
46 in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal
47 neurodegeneration.

48

49 INTRODUCTION

50 Once considered vestigial, the primary cilium has emerged as a key microtubule-based organelle
51 that senses external environment and modulates diverse signaling pathways in multiple tissues.
52 Aberrant cilium biogenesis and/or ciliary transport and functions lead to numerous diseases,
53 collectively termed ciliopathies, which manifest from sensory abnormalities to syndromic
54 disorders with multi-organ pathologies including aberrant kidney morphogenesis, brain
55 malformation, and congenital retinal degeneration (1). The mammalian retina is an extension of
56 the central nervous system that is specialized for vision (2). The visual information is captured
57 by rod and cone photoreceptors, integrated and processed by interneurons, and transmitted to the
58 cortex through the retinal ganglion cells. Inability of the retinal photoreceptors to detect and/or
59 transmit light-triggered signals is a major cause of vision impairment in retinal and macular
60 degenerative diseases (3-5). Mutations in over 200 genes can lead to inherited retinal diseases
61 (IRDs) (RetNET, <https://sph.uth.edu/retnet/>), with a combined prevalence of 1/3-4000
62 individuals (5, 6). Among them, up to 20% of IRD-causing genes are involved in primary cilium
63 biogenesis or functions (7). Due to extensive clinical and genetic heterogeneity, high inter- and
64 intrafamily variability, and incomplete penetrance (8), treatment options for IRD are limited (9).
65 Only one gene therapy drug is currently approved by FDA for Leber congenital amaurosis (LCA,
66 MIM204000) caused by *RPE65* mutations (10). While the initial clinical outcomes were
67 promising, the long-term data of this gene therapy drug are less encouraging (11). Furthermore,
68 development of individualized gene therapy protocols for divergent mutations in a multitude of
69 genes for rare IRDs would be time-consuming, expensive, and labor-intensive (12). Thus, gene-
70 agnostic paradigms are being developed for retinal and macular diseases using model organisms
71 and/or stem cell-based approaches (13). Small-molecule or antibody drugs represent a relatively

72 affordable and scalable option (12). However, over 90% of drug candidates fail in Phase I
73 clinical trials due to the lack of effective model systems which faithfully recapitulate the
74 pathophysiology of human diseases (14). The limited number of cells in the retina and challenges
75 in the maintenance of primary retinal cultures have also hindered the progress of therapeutic
76 development.

77 LCA is a clinically severe and genetically heterogeneous group of IRDs, leading to vision
78 loss in early childhood (15). *LCA10* caused by mutations in the cilia-centrosomal gene *CEP290*
79 (also called *NPHP6*) is one of the most common, accounting for over 20% of patients (16).
80 Mutations in *CEP290* exhibit pleiotropy with phenotypes ranging from LCA (affecting vision
81 and other sensory systems) to nephronophthisis, and Joubert and Meckel syndromes involving
82 multiple organ systems (17-21). The large 290 kDa centrosome-cilia protein CEP290 is
83 ubiquitously expressed and localized to the Y-links of the transition zone of primary cilia, where
84 it acts as a hub for connecting major protein complexes and likely performs a gating function
85 (17, 22-24). The *rd16* mouse carries an in-frame deletion in the myosin tail of CEP290, which
86 causes malformed connecting cilium (equivalent to the transition zone) and rudimentary outer
87 segment (the primary cilium of photoreceptor) structure, leading to rapid degeneration of
88 photoreceptors (25, 26). Additional studies have also demonstrated a critical role of CEP290 in
89 cilia biogenesis (24, 27-30). Thus, *LCA10* is considered a retinal ciliopathy caused by
90 hypomorphic mutations (31, 32) that eliminate some functions of CEP290 (33). Vision
91 impairment in early childhood of *CEP290*-LCA patients imposes a considerable burden on
92 families and society (34). Notably, these patients demonstrate sparing of the foveal cones even at
93 late stages of life, providing an attractive target for therapy (35). Gene replacement using AAV
94 vector is difficult because of the large coding region of *CEP290*. Thus, other strategies including

95 antisense oligonucleotides are currently under investigation (36-41). However, no approved
96 treatment is currently available for alleviating vision loss due to CEP290 defects.

97 Generation of three dimensional tissue organoids from induced pluripotent stem cells
98 (iPSCs) (42, 43) has revolutionized biological and disease-modeling investigations and created
99 opportunities for high-throughput screening (HTS) to design novel treatment paradigms (44).
100 Further refinements of human retinal organoid culture protocols have permitted high efficiency
101 and yield, developmental staging and higher reproducibility (45-48). Biogenesis of diverse cell
102 types in retinal organoid cultures largely recapitulate structural and temporal development of *in*
103 *vivo* human retina and can display intrinsic light responses mimicking those of primate fovea
104 (49-51). Patient iPSC-derived human retinal organoids demonstrate disease-associated
105 phenotypes and are being used to evaluate various therapeutic approaches (52, 53). However,
106 long and tedious generation protocols spanning 150+ days, inherent variability, and lack of
107 compatible HTS assays still pose challenges for the application of human retinal organoids for
108 developing therapies (54).

109 In this study, we aimed to establish a reliable drug discovery pipeline using an organoid-
110 based HTS platform with a goal to identify drug candidates for maintaining photoreceptor
111 survival in retinopathies, focusing initially on *LCA10*. For primary HTS of over 6000 bioactive
112 small molecules, we designed survival assays using *rd16* mouse iPSC-derived retinal organoids,
113 which showed compromised photoreceptor development and viability. An FDA-approved small
114 molecule drug reserpine was identified as an efficacious lead compound, which also enhanced
115 both rod and cone photoreceptor development/survival in *LCA10* patient iPSC-derived retinal
116 organoids as well as in the *rd16* retina *in vivo*. Transcriptomic analyses of drug-treated patient
117 organoids indicated modulation of cell survival pathways including p53 and proteostasis by

118 reserpine. Further examination validated mis-regulation of autophagy in patient organoids and
119 *rd16* retina and demonstrated partial restoration of proteostasis and improved ciliogenesis after
120 reserpine treatment. Our study thus establishes a cross-species drug discovery pipeline using
121 organoid-based HTS and identifies a repurposing drug candidate for maintaining photoreceptor
122 survival in *LCA10* patients. As the action mechanisms reserpine is partially through the
123 modulation of proteostasis, which could be a common pathological impact of ciliopathies,
124 reserpine and its derivatives could potentially serve as an effect treatment for patients with other
125 retinal ciliopathies.

126 **RESULTS**

127 **Establishment of an organoid-based HTS platform**

128 We designed an unbiased HTS assay to identify drug candidates that might improve
129 photoreceptor development and/or survival. For a primary screen, we chose mouse retinal
130 organoids because of a much shorter photoreceptor differentiation time and efficient generation
131 of rudimentary outer segments using our modified HIPRO protocol (55). We decided to use an
132 iPSC line derived from the *Nrl*-GFP containing *rd16* mice, which express green fluorescent
133 protein (GFP) in all rods and carry an in-frame deletion in the myosin tail domain of CEP290.
134 The *rd16* mice are a model of photoreceptor degeneration observed in *LCA10* patients (25) (fig.
135 S1A). The *rd16* mouse derived-iPSCs displayed similar morphology, proliferation rate, and stem
136 cell properties as those derived from the wild type (WT) (fig. S1B and S1C). WT and *rd16*
137 retinal organoids also showed comparable morphology at early stages of differentiation (Fig.
138 1A). However, at later stages, rod photoreceptors in *rd16* organoids displayed aberrant
139 morphology, with malformed or missing ciliary axoneme, connecting cilium and ciliary rootlets
140 (fig. S1D). We then performed flow cytometry analyses to evaluate differentiation of GFP+ rod

141 photoreceptors in the *rd16* organoid cultures, with a goal to identify quantifiable phenotypes for
142 HTS. The *rd16* organoids demonstrated as much as 50% lower organoid viability and almost
143 60% fewer GFP+ rod photoreceptors at day (D) 26 (Fig. 1B), when photoreceptor outer segment
144 biogenesis begins in mouse organoids (56).

145 These phenotypes in GFP+ *rd16* rod photoreceptors permitted the development of a HTS
146 screening platform to identify bioactive small-molecule drug candidates for augmenting rod cell
147 differentiation and/or survival (fig. S1E). To avoid variability of organoid cultures, we
148 dissociated *rd16* organoids into single cells at D25 and performed the drug treatment on two-
149 dimensional cultures from D26 to D28. The two-dimensional cultures recapitulated the
150 phenotypes detected in non-dissociated organoids, and *rd16* cells displayed lower viability and
151 fewer GFP+ rod cells at D28 compared to the WT (Fig. 1C).

152 Our drug discovery pipeline is illustrated in Fig. 1D. In the primary screens, *rd16* retinal
153 organoid-derived cells were treated with over 6,000 small molecules; of these, 114 compounds
154 revealed higher GFP signal intensity, indicating a positive effect on rod photoreceptor survival.
155 We then eliminated the compounds that showed toxicity or autofluorescence even in the absence
156 of GFP expression (false positives). Fourteen small molecule compounds were then selected for
157 further screening to identify a lead compound.

158 **Selection of the lead compound**

159 We then treated *rd16* retinal organoids with the 14 selected small molecules in a secondary
160 assay, which started at D22 and lasted for 3 days to maximize the drug effect without causing
161 toxicity (Fig. 2A). WT, untreated and treated *rd16* organoids were harvested at D29 to allow
162 sufficient period for restoration of photoreceptors. The lead compound was selected based on the
163 efficacy of the small molecule drugs to improve photoreceptor development and/or survival.

164 Immunostaining of rhodopsin and S-opsin, markers of rod and cone photoreceptors respectively,
165 was performed to quantify the drug effect (Fig. 2B). Rhodopsin is highly expressed and polarized
166 to the apical side of rod photoreceptors in the neural retina of WT organoids. In contrast, *rd16*
167 photoreceptors exhibited lower expression of rhodopsin and the polarity was considerably
168 diminished. Two of the compounds, B05 and to some extent B03, were able to enhance
169 rhodopsin expression, with B05 improving the polarity of expression in neural retina as well. We
170 note that S-cone photoreceptors are difficult to be maintained in mouse organoid culture (56);
171 nonetheless, compounds B01 and B05 were able to augment the expression and polarity of S-
172 opsin. Three of the 5 compounds (B01, B03, B05) that showed no toxicity revealed a significant
173 increase in rod and/or cone photoreceptors in D29 *rd16* organoids (Fig. 2C); of these, B05 was
174 the most effective molecule and chosen as the lead compound. Interestingly, the other 4
175 molecules (B01-B04) were found to be derivatives of B05, further validating our results. B05
176 was identified as reserpine, a small-molecule drug that has been approved by FDA for treatment
177 of hypertension and schizophrenia (57, 58), thereby holding a potential for drug repurposing
178 (Fig. 2D).

179 **Validation of reserpine on *LCA10* patient organoids**

180 To further examine the efficacy of the lead compound reserpine, we utilized iPSC-derived retinal
181 organoids from a previously-reported *LCA10* family (33), which comprised of a heterozygous
182 unaffected mother (referred as control henceforth) and two affected compound heterozygous
183 children (LCA-1 and LCA-2; fig. S2A and S2B). Immunoblot analysis of control and patient
184 organoids revealed a significant reduction of full-length CEP290 in patients (fig. S2C). Defects
185 in rod photoreceptor development and outer segment biogenesis were evident in the patient
186 organoids from D120 onwards as revealed by near loss of connecting cilium marker ARL13B

187 and absence or mislocalization of rod-specific protein rhodopsin (fig. S2D). In concordance with
188 the retained central cones in *LCA10*, cone photoreceptors were only slightly compromised at a
189 late stage of differentiation in patient organoids.

190 Given that photoreceptor outer segment biogenesis begins around D120 in organoids (47)
191 and aberrant phenotypes in patient organoids were detectable at this stage (fig. S2D), reserpine
192 was added to patient organoids at D107 at a concentration of 10 μ M, 20 μ M or 30 μ M based on
193 the EC₅₀ (half maximal effective concentration) in the primary screens (16.7 μ M) (Fig. 3A). We
194 could detect improved connecting cilium immunostaining and rod development as early as D125
195 with addition of 30 μ M reserpine (fig. S3A). Even using the lowest tested dose (10 μ M), we
196 observed more polarized rhodopsin and connecting cilium at the apical side of photoreceptors in
197 treated patient organoids, demonstrating a favorable effect of the drug (fig. S3A). The highest
198 tested dose of 30 μ M showed no toxicity in most batches of organoid differentiation. We note
199 that reserpine reportedly interferes with the sympathetic nervous system by inhibiting the
200 transport of neurotransmitters into presynaptic vesicles (59); yet, even at 30 μ M, no adverse
201 effect was detected on the development of ribbon synapses and presynaptic vesicles. In contrast,
202 we observed improved biogenesis of these structures in the outer plexiform layer of treated
203 patient organoids (fig. S3B). Additionally, no significant difference was evident in bipolar cells
204 and Müller glia of untreated and treated patient organoids (fig. S3B). Interestingly, reserpine-
205 treated patient organoids showed reduced GFAP immunostaining (fig. S3B), suggesting reduced
206 cellular stress upon drug treatment. We also noted variations in drug effects on organoids derived
207 from the two patients. While LCA-1 photoreceptors showed more opsin⁺ rod and cone
208 photoreceptors with the addition of 30 μ M reserpine, the improvement in LCA-2 organoids was

209 moderate (Fig. 3B). Such differences could be attributed to variability in response to dose and/or
210 treatment windows for the two donor organoids.

211 We then performed transmission electron microscopy to uncover additional structural
212 details of the primary cilium in photoreceptors of patient organoids after treatment. Reserpine
213 increased the percentage of mother centrioles harboring ciliary vesicles in LCA-1 patient
214 organoids (Fig. 3C and fig. S4A), which were reportedly missing in a significant fraction of LCA
215 photoreceptors (33). LCA-2 organoids demonstrated almost 50% more elongated ciliary
216 axonemes after reserpine treatment though ciliary vesicles were hardly noticed. Quantification of
217 the length of the ciliary axoneme indicated a significant increase in both patient organoids after
218 treatment (Fig. 3C). Notably, well-organized disc-like structures could be distinguished in treated
219 samples (fig. S4B), suggesting a positive impact of reserpine treatment on photoreceptor primary
220 cilium development.

221 **Implication of cell survival and proteostasis pathways in reserpine-treated organoids**

222 To elucidate the mechanism of action of reserpine and to gain insights into photoreceptor cell
223 death in *LCA10*, we performed RNA-seq analyses of control and patient retinal organoids. The
224 organoids were harvested right after the treatment with 30 μ M reserpine at D150 (fig. S5A).
225 Consistent with the moderate response of LCA-2 patient organoids to reserpine (Fig. 3B), we did
226 not identify significant differentially expressed (DE) genes between untreated and treated groups
227 of LCA-2 for downstream analyses (data not shown) and thereby focused only on LCA-1.
228 Principal component analysis (PCA) revealed substantial alterations in patient organoid
229 transcriptome compared to control and after reserpine treatment (Fig. 4A). The largest principal
230 component PC1 accounted for up to 36.2% of the total variation and is likely due to the drug
231 treatment. PC2 explained another 21% of the total variation and seemed to be mainly contributed

232 by the disease status. Notably, the reserpine-treated group was closer to the control compared to
233 the untreated group in PC2. A total of 356 genes were significantly differentially expressed
234 between untreated and treated organoids at thresholds of 5% FDR and 2-fold change. Consistent
235 with the PCA plot, heatmap analysis indicated that DE genes in treated patient organoids showed
236 relative transcriptomic shift from untreated ones towards the control ones (Fig. 4B). However,
237 compared to the controls, most of the downregulated genes (e.g., those involved proteostasis) in
238 untreated LCA-1 organoids had an even higher expression upon drug treatment. Similarly, the
239 expression of genes upregulated in untreated samples was lowered even more than the controls
240 by reserpine treatment. Curiously, treatment of LCA-1 organoids with 10 μ M or 20 μ M reserpine
241 did not yield sufficient DE genes for further analyses (data not shown).

242 We first analyzed the expression level of genes specific for different retinal cell types and
243 those involved in phototransduction and photoreceptor outer segment structure/function.
244 Reserpine treatment enhanced the expression of marker genes for inner retina cell types,
245 including Müller glia (fig. S5B); however, surprisingly, several rod and cone photoreceptor
246 genes (e.g., *OPN1SW* and *GRK7*) showed lower expression (Fig. 4C, fig. S5C), with *CEP290*-
247 associated cilia genes (23) exhibiting varying changes in expression (fig. S5D).

248 As reserpine did not seem to directly regulate the expression of key components involved
249 in disease pathology, we mapped the overexpressed genes to KEGG pathways and created an
250 enrichment network. Using a cutoff of 3 genes minimum overlap and 5% impact, the annotation
251 network was plotted to visualize leading ontology terms (Fig. 4D). Clusters of metabolism,
252 proteostasis, and immune pathways, together with cell survival related processes, were apparent
253 in the network. To better understand functional connectivity among DE genes, we performed
254 Random-walktrap analysis on their protein-protein interactions network to identify co-

255 functioning over- and under- expressing genes and identified three prominent modules (fig.
256 S5E). Functional module 1 was comprised of extracellular matrix (ECM) and ECM-receptor
257 interaction, and advanced glycation end products (AGE)-Receptor for AGE (RAGE) signaling
258 pathway genes. Müller glia-specific genes *MMPL14*, *TIMP1*, and *VIM* were included in this
259 module. Functional module 2 consisted of inflammation- and proteasome-related genes, which
260 are consistent with the reported role of reserpine as an autophagy modulator (60). Notably,
261 functional module 3 contained critical cell survival factors such as p53 signaling and cellular
262 senescence associated genes. We further investigated the trend of the p53 network to characterize
263 its role in response to drug treatment. Expression of *TP53*, the gene coding p53, was found to
264 increase and match the level of control organoids (fig. S5F). In addition, a widespread
265 modulation of each component of the p53 signaling network was evident upon reserpine
266 treatment (fig. S5G). Downstream targets of p53, including metabolic modulator TSC and
267 mTOR complex genes, responded to reserpine and returned to the level of control organoids (fig.
268 S5H). Two components of the mTORC1 signaling pathway, *RHEB* and *LAMTOR1*, were over-
269 expressed after the drug treatment. As mTORC1 is a key regulator of cellular metabolism, we
270 observed significantly elevated expression of *SLC2A1* (GLUT) which is the primary glucose
271 transporter in neurons (fig. S5I).

272 Given the reported actions of reserpine in neuronal cells (60), consistent with activation
273 of mTORC1 activation (61) and “proteasome” subunit-encoding genes (Fig. 4D), we performed
274 a focused gene set enrichment analysis to test the impact on the proteostasis network (PN). A PN
275 geneset was manually curated from KEGG and Reactome using keywords reviewed from
276 previous publications (62, 63). We detected a significant positive net enrichment of PN in patient
277 organoids after reserpine treatment (NES = 1.37, adj. p-value = 1.6e-11; Fig. 4E), as measured

278 by log₂ fold change in expression of all PN genes (Fig. 4F). We also identified global
279 overexpression of proteasomal subunits, some of which were notably induced with fold change >
280 2 (Fig. 4G). In concordance, expression of the key regulators of proteostasis and members of the
281 p53 network, p62 (*SQSTM1*) and NRF2 (*NFE2L2*), were significantly augmented in reserpine-
282 treated patient organoids (Fig. 4H and 4I).

283 **Restoration of proteostasis in patient photoreceptors**

284 To experimentally examine the role of PN in survival of *LCA10* photoreceptors, we
285 supplemented organoid cultures with various autophagy inhibitors (MRT68921, Lys05,
286 chloroquine, hydroxychloroquine, ROC-325) that target different steps of the autophagy pathway
287 (fig. S6A). MRT68921 and Lys05 inhibit the initiation of autophagy (64) and were highly toxic
288 even at one fourth of the reported EC₅₀. Curiously, hydroxychloroquine and ROC-325 but not
289 chloroquine enhanced the number of RHO⁺ cells in patient organoids with more polarized
290 localization of rhodopsin to the apical side (fig. S6B). Small molecule ROC-325, a more specific
291 and efficient autophagy inhibitor compared to hydroxychloroquine (65), demonstrated a more
292 dramatic effect on the rescue. Though hydroxychloroquine and ROC-325 were not as efficacious
293 as reserpine (fig. S6B), improvement in rod photoreceptors upon treatment provided further
294 evidence in support of the autophagy pathway as a target for designing therapies.

295 To further determine the role of autophagy, we evaluated the level of cargo receptor
296 sequestosome 1 (*SQTM1*) or p62, which recognizes cellular components and helps in formation
297 of autophagosomes for proteolysis (66)(Fig. 5A). We noted that LCA-1 patient organoids had a
298 significantly lower level of p62 compared to the control, and reserpine treatment significantly
299 elevated p62 levels by more than 2-fold (Fig. 5B), consistent with previous studies (60, 67).
300 Significantly higher levels of LC3-II in patient organoids also indicated accumulation of

301 autophagosomes (defects in autophagy), and reserpine treatment revealed a trend of decreasing
302 LC3-II levels (though not statistically significant) in patient organoids (Fig. 5B). The comparable
303 ratio of LC3-II/LC3-I indicated a similar rate of autophagosome formation between control and
304 patient organoids, suggesting that increased LC3-II levels in patient organoids could be due to
305 overexpression of autophagy pathway components. Consistent with the reported function of
306 reserpine as an autophagy inhibitor, the treated patient organoids had a significantly lower LC3-
307 II/LC3-I ratio, although we did not detect a significant difference between the control and patient
308 organoids (Fig. 5B).

309 We then applied Bafilomycin A1 (BafA1), an inhibitor of autophagosome-lysosome
310 fusion, to patient organoid cultures. A short 6-hour treatment with BafA1 did not alter the
311 autophagy pathway in the control, as shown by comparable levels of p62 and LC3-II as well as
312 LC3-II/LC3-I ratio (fig. S6C); however, patient organoids demonstrated a significant (up to
313 70%) increase of LC3-II and LC3-II/LC3-I ratio, suggesting an elevated autophagic flux in
314 patient organoids, consistent with the rescue by reserpine treatment.

315 The ubiquitin-proteasome system (UPS) and autophagy are the two key pathways in
316 proteostasis and are reported to interact through p62 (68, 69) (Fig. 5C). We therefore
317 investigated the response of UPS in patient organoids upon reserpine treatment. Untreated
318 patient organoids revealed a high level of 20S proteasome, which could be barely detected in the
319 control (Fig. 5D). Nonetheless, both the control and untreated patient organoids showed
320 comparable total catalytic activity and reserpine significantly elevated the proteasome activity
321 (Fig. 5E). These results suggest that increase in 20S expression is likely a compensatory
322 mechanism for compromised proteasome activity in patient organoids, and that reserpine
323 facilitates the clearance of accumulated cellular components and/or autophagosome (Fig. 5B).

324 We were intrigued by the reported links of autophagy to primary cilium biogenesis (70-
325 72) and therefore looked at the expression of key regulators involved in ciliary transport, cilium
326 assembly and disassembly (Fig. 5F). We identified higher expression of OFD1 (oral-facial-
327 digital syndrome 1), which when eliminated by autophagy is shown to promote ciliogenesis (71),
328 in patient organoids compared to the control even though autophagy activity was higher in the
329 latter (Fig. 5F). This apparent ambiguity could be due to variations in autophagic adapter
330 machinery for cargo identification. Nonetheless, reserpine treatment reduced OFD1 levels in
331 patient organoids and should facilitate initiation of cilia biogenesis. Another key regulator,
332 histone deacetylase 6 (HDAC6), which deacetylates microtubules and destabilizes the primary
333 cilium for disassembly (73, 74), was significantly elevated in patient organoids compared to the
334 control. Dramatic reduction of HDAC6 by reserpine (Fig. 5F) would also have a favorable
335 impact on cilia biogenesis. Consistent with this hypothesis, the addition of a selective HDAC6
336 inhibitor Tubastatin A to patient organoids improved rod photoreceptor development as shown
337 by a higher number of RHO⁺ cells (fig. S6D). Tubastatin A treatment enhanced the polarity of
338 not only rhodopsin but also S-opsin, likely due to increased stability of intracellular microtubules
339 and improved intracellular trafficking.

340 **Maintenance of photoreceptor survival in *rd16* mice *in vivo***

341 We then performed intravitreal injection of 40 μ M reserpine into *rd16* mouse eyes at postnatal
342 day (P)4, and the retinas were harvested at P21 (Fig. 6A). Reserpine was able to maintain
343 photoreceptor survival, with a significantly thicker outer nuclear layer (ONL) in both central and
344 peripheral retina (Fig. 6B). As a small molecule drug, reserpine is highly diffusive, and we
345 observed the effect of drug in contralateral eyes of the treated mice (fig. S7A). Indeed, bilateral

346 therapeutic effects have been reported following unilateral injection in clinical treatments (75-
347 79). Notably, no toxicity was observed in the treated mice (data not shown).

348 Further analyses confirmed an improvement in structure of photoreceptor outer segments
349 of the treated *rd16* retina. Reserpine partially restored outer segment axonemes that were largely
350 missing in untreated mouse retina (Fig. 6C). In addition, substantial ciliary rootlets were
351 conspicuous in the inner segment (shown by GFP) and extended into the ONL.
352 Phototransduction proteins including rhodopsin and Pde6 β were transported to the outer segment
353 region (fig. S7B). In addition, the treatment with 40 μ M reserpine led to better morphology of
354 other retinal cell types or structures including synapses, bipolar neurons and amacrine cells (fig.
355 S7C). Notably, reserpine treatment significantly reduced GFAP levels that expanded to the entire
356 retina in untreated mice (fig. S7C), suggesting alleviation of photoreceptor stress. Consistent
357 with the effects observed on human retinal organoids, reserpine treatment increased p62 levels
358 (Fig. 6D), dramatically reduced the 20S proteasome (Fig. 6E), and significantly enhanced the
359 proteasome activity (Fig. 6F).

360 **DISCUSSION**

361 Repurposing of existing drugs for new unrelated clinical modalities provides an excellent
362 opportunity for alleviating patient sufferings in a timely and cost-effective manner (80). HTS of
363 approved small molecule drugs can be based on simple assays that target the modulation of a
364 disease-related phenotype or molecule. The use of patient-derived iPSCs and their derivatives,
365 including differentiated cell types in two-dimensional or organoids in three-dimensional cultures,
366 have substantially enhanced the prospects of successful drug discovery (54, 81). Exciting
367 screening platforms are now being applied to retinal cells and organoids for drug discovery (44,
368 82). We note the success of cross-species screening, in which the drug candidates identified

369 using one species could be effective in another species (83). Given the “orphan” status of IRDs,
370 extensive genetic and phenotypic heterogeneity, and predominantly early dysfunction/death of
371 rods, we designed a simple assay using GFP-tagged rods from iPSCs of a mouse mutant that
372 phenocopies *LCA10* and established an HTS platform to identify small-molecule drugs to
373 maintain photoreceptor survival. As two-dimensional primary or stem cell-derived cultures
374 demonstrate a relatively lower variation and have generated promising candidates in screenings
375 (44, 84-86), we dissociated mouse retinal organoids into single cells and performed HTS in two-
376 dimensional cultures. The identified lead compound reserpine was subsequently verified to be
377 effective on patient organoids and in mouse mutant retina *in vivo*, suggesting the feasibility of
378 our approach for drug discovery.

379 Reserpine was approved for treatment of hypertension in 1955 and later for treatment of
380 schizophrenia (www.pubchem.gov); however, many better tolerated and more potent
381 hypertensive medications have become available during the last few decades. Though potential
382 side effects of inhibition of presynaptic vesicle formation and consequently depression have been
383 described for reserpine treatment (87), we did not observe adverse consequences on ribbon
384 synapses or presynaptic vesicles in treated organoids or *in vivo* mouse retina (fig. S3B and Fig.
385 7). Our results are consistent with a previous study demonstrating little effect of reserpine on
386 central sympathetic activity in cats (88). Additionally, the doses of reserpine for treatment of
387 hypertension or schizophrenia in adults range from 8 µg/kg to 80 µg/kg for a 60 kg adult (89),
388 which are higher than the dose we used in mouse studies (9.6 µg/kg). Besides, local delivery by
389 intravitreal injection or via eye drops should be sufficient for reserpine to elicit its effects in the
390 retina due to highly diffusive property of small-molecule drugs. Thus, we suggest that reserpine
391 could be a safe therapeutic approach for treatment of *LCA10* and probably other retinal

392 ciliopathies. Future studies will focus on toxicity evaluation as well as on identifying more
393 potent and less toxic derivatives of reserpine to initial clinical trials.

394 Transcriptomic analyses have permitted us to interrogate potential mechanism(s) of
395 reserpine action in patient organoids and implicated signaling pathways involved in immune
396 response (e.g., primary immunodeficiency, complement and coagulation cascade), cell survival
397 and cell death (e.g., p53 signaling pathway, cellular senescence, apoptosis), metabolism (e.g.,
398 glutathione metabolism, purine metabolism), and proteostasis. Indeed, these pathways have
399 highly intricate relationships. The p53 protein acts as a sensor of stress conditions and can act
400 both as a transcriptional activator or repressor to promote cell death and cell survival decisions
401 (90-92). Gene profiles of treated patient organoids revealed a significant increase of *TP53* as
402 well as its downstream targets including key cellular metabolic regulator TSC and mTOR
403 complex. More importantly, the expression level of genes involved in TSC and mTOR complex
404 returned to the level of control organoids, suggesting a positive impact of reserpine in restoring
405 photoreceptor metabolism. As both TSC knockout and mTOR complex 1 activation are reported
406 to maintain photoreceptor survival (93, 94), the trends in our experimental system suggest a cell
407 survival effect of the p53 pathway through the modulation of cell metabolism. In addition, the
408 expression of several Müller glia-specific genes was altered by reserpine, with GFAP levels
409 reduced in both organoids and mouse retina *in vivo*. Müller glia are believed to play a major role
410 in reactive gliosis and likely adapt their transcriptome to support photoreceptors in retinal
411 degeneration (95, 96). Yet, we are unsure whether reserpine directly acts on Müller glia to
412 augment photoreceptor survival, or its response is a consequence of improved microenvironment
413 and reduced retinal stress. Notably, the primary cilium appears to have a role in Müller glia
414 maturity and functions in primary cultures (97). Whether and how Müller glia are affected in

415 *LCA10* or other degenerative diseases and their role in photoreceptor survival are active areas of
416 investigation.

417 One of the downstream effectors of p53 and mTOR for metabolic control is the
418 autophagy pathway (90, 98). Autophagy is a fundamental homeostatic pathway that serves as a
419 key quality control mechanism for degradation and recycling of components in all tissues,
420 including highly metabolic tissues such as photoreceptors (99, 100). Reserpine's reported role as
421 an autophagy modulator (60, 101) is consistent with photoreceptor survival in general (99, 102-
422 105), and especially in CEP290 disease because of the purported connection between autophagy
423 and ciliogenesis (71, 72). Ciliary defects in photoreceptors promote apoptotic cell death through
424 accumulation of outer segment proteins (e.g., opsin) in the endoplasmic reticulum (ER) and
425 subsequent activation of the unfolded protein response (UPR) (1) to restore protein homeostasis
426 in ER. Pharmacological modulation of UPR can preserve photoreceptors in a BBS12 model of
427 syndromic ciliopathy Bardet-Biedl Syndrome (106). Recently, CEP290 is shown to be involved
428 in aggresome assembly for protein degradation (30), although it is unclear whether this process is
429 disrupted in *LCA10*. Therefore, *CEP290* mutation(s) could lead to accumulation of photoreceptor
430 cilia proteins and ER stress. In agreement, we observed increased autophagic flux in *LCA10*
431 patient organoids. Though it seems counterintuitive to reduce autophagic flux as the accumulated
432 protein would aggravate disease pathology, we hypothesize that reserpine not only acted as an
433 autophagy inhibitor to reduce autophagic flux but also activated UPR to facilitate protein
434 clearance in patient organoids through p62, the common cargo adaptor of the two systems (Fig.
435 7). We note that inhibition of autophagy or activation of proteasome activity can maintain
436 photoreceptors survival in mouse models with misfolded rhodopsin (104). As autophagy defects
437 are associated with retinal degeneration (99, 105), reserpine holds promise to serve as a gene

438 agnostic therapy. Interestingly, a favorable effect of autophagy inhibition has also been reported
439 for retinal ganglion cell survival (107).

440 Improved outer segment biogenesis is another prominent effect of reserpine in our study.
441 As a key signaling regulator, the primary cilium is essential for the activation of starvation-
442 induced autophagy through modulation of the Hedgehog pathway and other components
443 involved in autophagy, which can eliminate components in intraflagellar transport (70) as well as
444 remove OFD1 from distal appendages to initiate cilium biogenesis (71). Thus, the outcome of the
445 crosstalk between ciliogenesis and autophagy seems to largely depend on cell type and
446 physiological context. Our observation of high OFD1 levels in patient organoids compared to the
447 control, despite an elevated autophagic flux, suggests alternative mechanisms. HDAC6 has also
448 been demonstrated to promote autophagosome maturation (108, 109) as well as deacetylate
449 microtubules to impede intracellular trafficking, which is a key driver of primary cilium
450 disassembly. Higher expression of HDAC6 in patient organoids could explain both the failure of
451 docking of pre-ciliary vesicles (33) and elevated autophagic flux in patient photoreceptors.
452 HDAC6 is shown to be a target of p62 for degradation, and an increase in p62 in photoreceptors
453 can reduce HDAC6 leading to improved outer segment length (110). We suggest that reserpine-
454 induced p62 levels can facilitate the degradation of HDAC6 and augment intracellular transport
455 of preciliary vesicles to the mother centriole for cilia biogenesis.

456 In conclusion, we identified a repurposing small-molecule drug reserpine to maintain
457 photoreceptor survival in retinal ciliopathies, specifically *LCA10*, and at least partially acting by
458 restoration of proteostasis in photoreceptors. Reserpine has been evaluated in a human context
459 (using patient organoids) and mouse retina *in vivo* and thus holds promise in future clinical
460 studies. As the loss of proteomic homeostasis is a major cause of multiple retinal degenerative

461 diseases (*III*), reserpine and its derivatives have clinical potential for gene-agnostic therapies.
462 We realize that we have not examined retinal function and long-term maintenance of
463 photoreceptors in *rd16* mouse. The dose and treatment window of intravitreal injection would
464 require further optimization. In addition, despite the identification of pathways associated with
465 reserpine action, it is hard to dissect the function of each pathway as they are highly intertwined
466 with each other. We should also mention that the drug candidate we identified using mouse
467 organoids is effective on patient organoids and mouse retina *in vivo*; however, certain
468 pathogenetic pathways specific to humans might be missing in the drug target search by current
469 HTS strategy. A major future direction will be to evaluate the effect and safety of reserpine on
470 photoreceptor survival and function in multiple degenerative mouse models and using patient
471 iPSC-derived retinal organoids of other ciliopathies in IRD.

472 **MATERIALS AND METHODS**

473 **Mouse and human pluripotent cell lines**

474 The mouse *Nrl*-GFP wild-type (WT) and *rd16* induced pluripotent stem cell (iPSC) lines were
475 reprogrammed from fibroblasts of day 14.5 mouse embryos as previously described (55). The
476 generation and characterization of the familial control, LCA-1 and LCA-2 iPSC lines have been
477 previously reported as well (33).

478 **Animals**

479 *B6.Cg-Cep290rd16/Boc* mice (Strain #: 012283; RRID: IMSR_JAX:012283) were obtained
480 from the Jackson Laboratory and crossed to *Nrlp-EGFP* mice to generate *Nrlp-EGFP*;
481 *Cep290^{rd16/rd16}* mice (referred to as *rd16*). The absence of the *rd8* mutation in the colony was
482 assessed by PCR. All animal procedures were approved by the Animal Care and Use committee
483 of the National Eye Institutes (Animal study protocol NEI-650) and adhered to ARVO Statement

484 for the Use of Animals in Ophthalmic and Vision Research. Mice were housed in an atmosphere-
485 controlled environment (temperature: 22°C ± 2°C, humidity: 30%–70%), under a 12-hour
486 dark/12-hour light cycle and supplied with food and water ad libitum. Food, water, and nesting
487 material were changed weekly.

488 **Compound libraries**

489 We used three different small molecule libraries for our screening efforts. The library of 1,280
490 pharmacologically active compounds (LOPAC 1,280) consists of a collection of small molecules
491 with characterized biological activities commonly used to test and validate screening assays. The
492 library of U.S. Food and Drug Administration (FDA)-2800 approved drugs were set up
493 internally. The compounds were first dissolved in 100% DMSO to generate a stock concentration
494 with a final concentration of 10 mM and subsequently diluted into 7 concentrations and
495 dispensed into 1536-well plates. The NCATS Mechanism Interrogation Plate (MIPE) 5.0 library
496 contains a collection of 1912 compounds (approved for clinical trials).

497 **Maintenance of induced pluripotent stem cells**

498 The WT and rd16 iPSC lines were maintained as previously described (112). Briefly, the iPSC
499 lines were maintained on feeder cells (Millipore) in maintenance medium constituted by
500 Knockout DMEM (ThermoFisher Scientific), 1x MEM non-essential amino acids (NEAA)
501 (Sigma), 1x GlutaMAX (ThermoFisher Scientific), 1x Penicillin-Streptomycin (PS)
502 (ThermoFisher Scientific), 2000 U/ml leukemia inhibitory factor (LIF) (Millipore), and 15% ES
503 cell-qualified fetal bovine serum (FBS) (ThermoFisher Scientific) at 37°C, 5% CO₂. Full media
504 change was performed every day, with 55 µM β-Mercaptoethanol (2-ME) (ThermoFisher
505 Scientific) freshly added. Cells were passaged using TrypLE Express (ThermoFisher Scientific)
506 every two days.

507 Human iPSC lines were maintained in Essential 8 (E8) (ThermoFisher Scientific) on
508 growth factor-reduced (GFR) Matrigel (Corning)-coated plates, with media fully changed daily.
509 Cells were maintained at 37°C, 5% O₂, 5% CO₂ and passaged at 60-80% confluency using the
510 EDTA-based dissociation method (113).

511 **Differentiation of mouse and human retinal organoids**

512 The modified HIPRO protocol was used to differentiate mouse iPSCs into retinal organoids (55,
513 112). At differentiation day (D)0, iPSCs were plated in low adhesion U-shaped 96-well plate
514 (Wako) at a density of 3000-5000 cells per well in 100 µl retinal differentiation medium
515 consisting of GMEM (ThermoFisher Scientific), 1x NEAA, 1x sodium pyruvate (Sigma) and
516 1.5%(v/v) knockout serum replacement (KSR) (ThermoFisher Scientific). At D1, 240 µl GFR-
517 Matrigel (>9.5 mg/ml) was diluted in 1.8 ml retinal differentiation medium and 20 µl diluent was
518 aliquoted to each well of the 96-well plate. Retinal organoids from one 96-well plate were
519 transferred to a 100 mm poly(2-hydroxyethyl methacrylate) (Sigma)-coated petri dish with 12 ml
520 DMEM/F12 with GlutaMAX, 1x N2 supplement and 1x PS. The media were replaced by
521 DMEM/F12 with GlutaMAX, 1x PS, 1x N2 supplement, 1 mM taurine (Sigma), 500 nM 9-*cis*
522 retinal (Sigma) and 100 ng/ml insulin-like growth factor 1 (IGF1) (ThermoFisher Scientific) at
523 D10, and half-media change was performed every other day, with 55 µM 2-ME freshly added to
524 the media. From D26 and onward, 1x NEAA, 1x B27 supplement without Vitamin A
525 (ThermoFisher Scientific) and 2%(v/v) FBS (ThermoFisher Scientific) were added to the culture.
526 Half-media exchanges were performed every two days, with 55 µM 2-ME freshly added to
527 media. The cultures were incubated in 5% O₂ from D0 to D10 and in 20% O₂ from D10 onwards.

528 Human retinal organoid differentiation was performed as previously described (114).

529 Briefly, small clumps dissociated from iPSCs in one well of a 6-well plate were resuspended in

530 E8 medium supplemented with 10 μ M Y-27632 (Tocris) and transferred into one 100-mm
531 polyHEMA-coated petri dish for embryoid body (EB) formation. Media were supplied with
532 neural induction media (NIM) (DMEM/F-12 (1:1) (ThermoFisher Scientific), 1x N2 supplement,
533 1x NEAA, 2 μ g/ml heparin (Sigma) at D1 and D2 at a ratio of 3:1 and 1:1 respectively, and fully
534 switched to NIM at D3. D7 EBs from one 100-mm petri dish were plated onto one GFR
535 Matrigel-coated 60 mm dish and cultured in NIM, with media changed every 2-3 days. In the
536 application requiring a large-scale production of retinal organoids, nicotinamide was added to the
537 culture to reach a final concentration of 5 mM from D0 to D8 (48). NIM was replaced by 3:1
538 retinal induction medium (RIM) consisting of DMEM/F-12 supplemented with 1x B27 without
539 Vitamin A (ThermoFisher Scientific), 1% antibiotic-antimycotic solution (ThermoFisher
540 Scientific), 1% GlutaMAX and 1X NEAA at D16 and media change was performed every day
541 until D28, on which the adherent cells were scraped off into small clumps ($<5 \text{ mm}^2$) and split
542 into two polyHEMA-coated 100-mm petri dishes. The floating clumps were cultured in RIM
543 supplemented with IGF1 (ThermoFisher Scientific) and 1 mM taurine (Sigma), with 55 μ M 2-
544 ME freshly added. From D38 and onward, 10% fetal bovine serum was added to RIM
545 supplemented with 20 ng/ml IGF-1, and 1 mM taurine. 1 μ M 9-*cis* retinal was freshly
546 supplemented to the cultures during media change from D63 to D91. From D91 till the end of
547 differentiation, the concentration of 9-*cis* retinal was reduced to 0.5 μ M and B27 without
548 Vitamin A was replaced by N2. Once scraped, media were half changed every 2-3 days, with
549 IGF1, taurine and 9-*cis* retinal freshly added to the media under dim light environment.

550 **Dissociation of mouse retinal organoids into single cells**

551 Mouse retinal organoids were transferred into a 15 ml centrifuge tube using wide-bored transfer
552 pipets and washed one time with 10 ml 1x PBS (ThermoFisher Scientific). Prewarmed 1 ml

553 0.25% trypsin-EDTA was then added, and the tube was incubated s at 37°C for 10 minutes, with
554 pipetting up and down for 10 times using P1000 pipetman at 5- and 10-minute incubation. 10 ml
555 retinal maturation media (DMEM/F12 with GlutaMAX, 1x PS, 1x N2 supplement, 1 mM
556 taurine, 500 nM 9-*cis* retinal, 1x NEAA, 1x B27 supplement without Vitamin A, 2%(v/v) FBS)
557 was added to the tube. The tube was inverted several times before centrifugation at 200g for 5
558 minutes. After removal of supernatant, the cell pellet was resuspended in 1 ml retinal maturation
559 media and filtered through 40- μ m cell strainer (BD Bioscience) before proceeding to subsequent
560 analyses.

561 **Immunoblot analysis**

562 At least 3 organoids in each batch were homogenized in 100 μ l of RIPA buffer (Sigma)
563 supplemented with 1x protease inhibitors (Roche) and 1x phosphatase inhibitor (Roche). The
564 lysate was agitated at 4°C for half an hour, before centrifugation at 12,000g for 10 minutes at
565 4°C. The supernatant was either stored at -80 °C until use or quantified by Pierce bicinchoninic
566 acid (BCA) protein assay (ThermoFisher Scientific). Approximately 20 μ g protein was diluted
567 4:1 in reducing 4x Laemmli buffer (Biorad) and boiled for 10 minutes. The samples were
568 separated at 150-180 V for 1 hour on 4-15% precast polyacrylamide gel (Biorad) and transferred
569 to polyvinylidene fluoride (PVDF) membranes using a TransBlot® Turbo™ Transfer System
570 (Biorad). After blocking in 5% milk or 5% bovine serum albumin (BSA) for 1 hour at room
571 temperature, the blots were incubated in antibody cocktails (Table S1) overnight in 1% milk or
572 BSA in 1X TBS-T at 4 °C overnight with gentle agitation. Membranes were subsequently
573 washed in 1X TBS-T for 3 times, 10 minutes each, and incubated in 1X TBS-T with horseradish
574 peroxidase-conjugated secondary antibodies (1:5,000) for 1 hour at room temperature, followed
575 by another three 10-minute wash. Before imaging, the membranes were exposed to

576 SuperSignal® West Pico enhanced chemiluminescence (ECL) solution (ThermoFisher
577 Scientific) for 5 minutes, and chemiluminescence was captured using a Bio-Rad ChemiDoc™
578 touch (Bio-Rad).

579 **Chymotrypsin-like proteasome activity assay**

580 The chymotrypsin-like protease activity associated with the proteasome complex in organoids or
581 mouse retina was quantified using the Proteasome 20S Activity Assay Kit (Sigma) following
582 manufacturer's protocol. In short, at least 3 retinal organoids or 1 mouse retina were
583 homogenized in 55 µl PBS mixed with 55 µl reconstituted Proteasome Assay Loading Solution
584 and incubated on ice for 30 minutes. After centrifuging at 10,000 g for 10 minutes at 4 °C, 10 µl
585 supernatant was taken for BCA assay to determine the protein amount and the remaining 100 µl
586 was transferred to one well of black/clear 96-well plate for incubation at 37 °C. Protease activity
587 of individual samples was measured by the fluorescence intensity ($\lambda_{ex} = 480\text{--}500\text{ nm}$ / $\lambda_{em} =$
588 $520\text{--}530\text{ nm}$) normalized to the protein amount.

589 **Transmission electron microscopy**

590 Retinal organoids were processed for transmission electron microscopy (TEM) analysis as
591 previously described (33). Briefly, the organoids were fixed in 4% formaldehyde and 2%
592 glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 (Tousimis) for 2 hours at room temperature,
593 followed by 3 washes in cacodylate buffer before further fixation in osmium tetroxide (1% v/v in
594 0.1 M cacodylate buffer; Electron Microscopy Sciences) for 1 hour at room temperature. The
595 organoids were then washed in the same buffer for three times, followed by 1 wash in acetate
596 buffer (0.1 M, pH 4.2), and *en-bloc* staining in uranyl acetate (0.5% w/v; Electron Microscopy
597 Sciences) in acetate buffer for 1 hour at room temperature. The samples were dehydrated in a
598 series of ethanol solutions (35%, 50%, 75%, 95%, and 100%) and then by propylene oxide. The

599 samples were subsequently infiltrated in a mixture of propylene oxide and epoxy resin (1:1, v/v)
600 overnight, embedded in a flat mold with pure epoxy resin, and cured at 55 °C for 48 hours. 70-80
601 nm sections were made with an ultramicrotome (UC 7) and diamond knife (Diatome), attached
602 on a 200-mesh copper grid, and counter-stained in aqueous solution of uranyl acetate (0.5% w/v)
603 and then lead citrate solutions. The thin sections were stabilized by carbon evaporation before
604 the EM examination. The digital images were taken using a digital camera equipped with an
605 electron microscope (H7650) (AMT).

606 **Flow cytometry**

607 After dissociating retinal organoids, the cells were resuspended in DPBS (ThermoFisher
608 Scientific) containing 1 mM EDTA (Millipore) and filtered through a 40- μ m cell strainer. 4',6-
609 diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific) was added to the samples before
610 being analyzed by FACSARIAII (BD Bioscience). Cell viability was evaluated by integrity (gated
611 by DAPI), size (gated by forward scatter, FSC) and granularity (gated by side scatter, SSC). WT
612 retinal organoids without GFP marker on the same differentiation day were used to set the gating
613 for GFP+ cells.

614 **RNA extraction and library preparation**

615 Total RNA was purified from homogenized retinal organoids using TriPure isolation reagent
616 (Roche). Quality of isolated RNAs was assessed using Bioanalyzer RNA 6000 nano assays
617 (Agilent) and high-quality total RNA (RNA integrity number ≥ 7.5) were used for construction of
618 mRNA sequencing library. 100 ng total RNA were used to construct the strand-specific libraries
619 using TruSeq RNA Sample Prep Kit-v2 (Illumina).

620 **RNA-seq data analysis**

621 RNA sequencing was performed as described (115). Paired-end 125-bp reads were generated
622 using Illumina sequencing. Reads were quality checked and mapped to the reference
623 transcriptome using Kallisto. Alignments were imported into R using tximport for downstream
624 analyses. The edgeR and limma pipeline were employed for differential expression analysis,
625 while pathway annotation was performed using ClueGO (116). Protein interaction data was
626 obtained from STRING (v11.5) with evidence cut off of 700, via the R package STRINGdb
627 (117). Network analysis was performed using the *igraph* package [<https://igraph.org>] and genes
628 were mapped to pathways using gProfileR (118). Proteostasis network genes were manually
629 collected by pooling KEGG and Reactome pathways with keywords from (62) and (63), and the
630 proteosome map was adapted from KEGG (hsa03050). Gene set enrichment analysis was done
631 using the R package fgsea. All other plotting and analyses, unless otherwise mentioned, were
632 performed using tidyverse and base R packages.

633 **Immunohistochemistry**

634 Mouse and human organoids were fixed in 4% PFA (Electron Microscopy Sciences) for 1 hour
635 at room temperature, washed 1 time and cryoprotected in 15% sucrose for at least 2 hours at
636 room temperature, followed by 30% sucrose at 4°C overnight. The next day, organoids were
637 embedded in Shandon M-1 Embedding Matrix (ThermoFisher Scientific). The blocks were
638 sectioned at 10 µm thickness and incubated at room temperature for at least 1 hour, before
639 immunostaining or storage at -80 °C. After incubating in blocking solution (5% donkey serum in
640 PBS) for 1 hour at room temperature, the sections were supplied with diluted primary antibodies
641 (Table S1) at 4°C overnight. After three 10-min washes in PBS, Species-specific secondary
642 antibodies conjugated with Alexa Fluor 488, 568 or 637, together with DAPI, were diluted in
643 blocking solution (1:500; ThermoFisher Scientific) and incubated with the sections for 1 hour at

644 room temperature. After washing in PBS for three times, 10 minutes each, the sections were
645 mounted for imaging.

646 For mouse retinal sections, rd16 mice of both sexes were injected at postnatal (P) day 4
647 and recovered at P21 after euthanasia using CO₂ atmosphere. Eyes were denucleated before
648 being pierced in the center of the cornea using a 26-gauge needle. Eyecups were then incubated
649 for 15 min in 4% paraformaldehyde (PFA). The cornea and lens were then dissected, and the
650 eyecups were placed in 4% PFA for 15 min at room temperature (RT) before proceeding to
651 cryoprotection in 20% and 30% sucrose-PBS at 4C for 1 hour and overnight, respectively.
652 Eyecups were then quickly frozen in Shandon™ M-1 Embedding Matrix (Thermo Fisher
653 Scientific) and cut at 12µm. Retinal sections were washed twice in PBS then blocked in PBS
654 containing 5% Donkey serum and 0.3% Triton X-100 (PBST) for 1 hour at room temperature.
655 Slides were incubated overnight at 4°C with primary antibody diluted in PBST at an appropriate
656 concentration (Table S1). Sections were then washed 3 times with PBS and incubated with
657 secondary antibody and 1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) for 1 hour at room
658 temperature. After 3 washes in PBS, the sections were mounted in Fluoromount-G
659 (SouthernBiotech).

660 **Image acquisition and analysis**

661 Brightfield images were taken using an EVOS XL Core Cell Imaging System (ThermoFisher).
662 Fluorescence images were acquired with LSM-880 confocal microscope (Zeiss) with Zen
663 software. FIJI and Photoshop CC 2019 software were used for images export, analyzing and
664 processing. Rhodopsin and S-opsin fluorescent intensity of organoid sections were quantified
665 with FIJI using the maximum intensity projections of z-stack images. Multi-channel RGB (red,
666 green, blue) images were separated into 8-bit grayscale images and regions of interest were

667 identified by applying the “Moment” threshold algorithm of FIJI. The same threshold algorithm
668 was used for all images. Area, raw and integrated fluorescence intensity in each image were then
669 quantified with Fiji and plotted using RStudio version 1.1.463.

670 **High-throughput screening (HTS) assays**

671 To optimize the assay for HTS, D25 WT and *rd16* mouse retinal organoids were
672 dissociated into single-cell suspension and plated in 5 μ l retinal maturation medium II at a
673 concentration of 3000, 4000, and 5000 cells per well in a 1536-well plate. After culturing in a
674 37°C humidified incubator overnight, 5000 cells/well yielded an optimal plating density for both
675 WT and *rd16* cultures and were selected for subsequent assays.

676 In the screening experiments for drug candidates, dissociated D25 WT-positive control
677 and *rd16* mouse retinal organoids were filtered through 35- μ m cell strainer and dispensed into
678 1536-well plate at a density of 5000 cells/well in 5 μ l freshly prepared retinal maturation
679 medium II using the Multidrop Combi Dispenser (Thermo Scientific). Cells were incubated in a
680 37°C humidified incubator overnight for cell recovery and attachment to the plates. Compounds
681 in the 1536-well drug source plates were added to the 1536-well assay plates at a volume of 23
682 nl/well using an NX-TR pintool station (WAKO Scientific Solutions). Cells were treated with
683 compounds for 48 hours, followed by addition of 0.5 μ l quencher, and GFP and DAPI signal
684 intensities were quantified using the acumen® Cellista (TTP, Labtech). The positive hits with a
685 significant increase of GFP compared to the DMSO-treated cells were retested using dissociated
686 retinal organoids from iPSCs without GFP marker to remove autofluorescent false positives. The
687 remaining drug candidates were further tested using a full 11-concentration setting (1:3 serial
688 dilutions starting at 10 mM) in triplicate plates to prioritize the hits based on efficacy.

689 The primary and confirmatory screening data were analyzed using software developed
690 internally at the NIH Chemical Genomics Center (NCGC) (119). The plate data was processed as
691 follows: We first ran quality control on the plate data by visual inspection, masking wells
692 showing erroneous signals, e.g., localized groupings of wells exhibiting enhanced or inhibited
693 signal. We then performed intra-plate normalization as follows:

$$694 \text{ Efficacy} = 100 \times \frac{GFP(RD16+C) - GFP(RD16+DMSO)}{GFP(WT+DMSO) - GFP(RD16+DMSO)} \quad [1]$$

$$695 \text{ Toxicity} = -100 \times \frac{DAPI(RD16+C) - DAPI(RD16+DMSO)}{DAPI(RD16+DMSO)} \quad [2]$$

$$696 \text{ Fluorescence} = 100 \times \frac{GFP(Parental+C) - GFP(Parental+DMSO)}{GFP(WT+DMSO) - GFP(Parental+DMSO)} \quad [3]$$

697 Where:

698 WT = D25 WT retinal organoid cells with GFP marker = GFP +

699 RD16 = D25 *rd16* retinal organoid cells with GFP marker = GFP -

700 Parental = Retinal organoids from iPSCs without GFP marker = GFP-

701 C = compound tested

702 GFP = GFP (channel 488) signal intensity

703 DAPI = DAPI (channel 405) signal intensity

704 When the data is normalized in this fashion, efficacy, toxicity, and fluorescence range from 0 to

705 100%. With this normalization completed we compute dose response curves as follows:

$$706 A(C_i) = A_0 + \frac{(A_\infty - A_0)}{[1 + (10^{(\log(Ac50) - \log(C_i))n})]} \quad [4]$$

707 Where C_i = the i 'th concentration, $A(C_i)$ = activity (efficacy, toxicity, or fluorescence) at

708 concentration i , A_0 = activity at zero concentration, A_∞ = activity at infinite concentration, and

709 EC_{50} = the concentration giving a response half-way between the fitted top (100%) and bottom

710 (0) of the curve.

711 Compounds are desired that have high efficacy ($EC_{50\text{efficacy}} = \text{small}$, $A_{\infty, \text{efficacy}} = \text{high}$), low
712 toxicity, ($EC_{50\text{toxicity}} = \text{large}$) and low fluorescence ($EC_{50\text{fluorescence}} = \text{large}$)

713 $EC_{50\text{toxicity}} / EC_{50\text{efficacy}} \gg 1$ [5]

714 $EC_{50\text{fluorescence}} / EC_{50\text{efficacy}} \gg 1$ [6]

715 $A_{\infty, \text{efficacy}} = \text{high}$ [7]

716 In addition, the dose response curves for each measured quantity must be well behaved, i.e., (i)
717 curves exhibit values near zero at low concentration, (ii) values increase with increasing
718 concentration, (ii) curves show a well-defined inflection point at the EC_{50} concentration, and (iv)
719 curves show a well-defined plateau at high concentration (119).

720 **Intravitreal injection**

721 Animal experiments were conducted in the animal facility at National Eye Institute, National
722 Institutes of Health. The facility approved the animal care and experimental procedures used in
723 this study (NEI-ASP650). P4 *Nrl*-GFP *rd16* mice pups of either sex were anesthetized on ice and
724 their eyelids were opened using a 30-gauge needle to gently expose the eye. 1mg/ml Ketoprofen
725 was injected for analgesia. Half microliter of solution diluted in PBS was blindly delivered using
726 a glass micropipette (World Precision Instruments) produced using a Flaming-Brown
727 micropipette puller (Sutter Instruments) and connected to an Eppendorf Femtojet air compressor
728 (Eppendorf). Mice with eye/lens damage following the injection were excluded from further
729 analyses.

730 **Statistics**

731 Based on the initial data, the sample size of animals used in each group was determined by
732 unpaired t-test to be less than 6 mice in each group (<http://www.biomath.info/>). For experiments
733 involved mouse or human retinal organoids, at least four independent experiments, each of

734 which had at least 3 organoids, were performed unless specified. For animal studies, at least 2
735 retina from 1 mouse of at least 4 different litters was evaluated. All data were expressed as mean
736 \pm standard deviation (SD) unless specified. An unpaired two-tailed Student's *t* test was used to
737 compare the mean between two groups. For comparison of three groups, one-way ANOVA
738 followed by Tukey's test was performed. Results with a *p*-value < 0.05 were considered
739 statistically significant.

740

741 **ACKNOWLEDGMENTS**

742 We thank Tiansen Li, Linn Gieser, Matthew Brooks, Ryan A. Kelley and Trupti Shetty in
743 Neurobiology, Neurodegeneration & Repair Laboratory of the National Eye Institute and
744 Wenwei Huang in National Center for Advancing Translational Sciences for technical support
745 and insightful discussions. We are grateful to Rafael Villasmil, Julie Laux, Jessica Albrecht, and
746 Jacqueline Minehart (Flow Cytometry Core Facility of the National Eye Institute), Lijin Dong,
747 Pinghu Liu, and Jingqi Lei (Genetic Engineering Core Facility of the National Eye Institute),
748 Jizhong Zou and Jeanette Beers (iPSC Core Facility at National Heart, Lung, and Blood
749 Institute), Sandra Burkett (Molecular Cytogenetic Core Facility at National Cancer Institute), and
750 Alan Hoofring and Ethan Tyler (Division of Medical Arts at National Institutes of Health) for
751 assistance in various aspects of research. These studies were supported by the high-performance
752 computational capabilities of the Biowulf Linux cluster at the National Institutes of Health
753 (<http://biowulf.nih.gov>). The work was supported by National Eye Institute Intramural Research
754 Programs (ZIAEY000450 and ZIAEY000546) and National Center for Advancing Translational
755 Sciences Intramural Research Programs ZIATR000018-06.

756 **COMPETING INTERESTS**

757 HYC, MS, SP, AJM, GT, WZ and AS are listed as inventors on a patent application related to
758 the small molecules in this study by National Institutes of Health. Other authors declare that they
759 have no competing interests.

760 **DATA AVAILABILITY STATEMENT**

761 All data needed to evaluate the conclusions in the paper are present in the paper and/or the
762 Supplementary Materials. RNA-seq data are available through GEO accession #206959.

763 **MATERIAL AVAILABILITY STATEMENT**

764 All pluripotent stem cell lines and animals are available upon request. A Material Transfer
765 Agreement complying with the guidelines of National Institutes of Health has to be established
766 before shipment.
767

768 **REFERENCES**

- 769 1. Reiter JF, and Leroux MR. Genes and molecular pathways underpinning ciliopathies. *Nat Rev Mol Cell*
770 *Biol.* 2017;18(9):533-47.
- 771 2. London A, Benhar I, and Schwartz M. The retina as a window to the brain—from eye research to CNS
772 disorders. *Nat Rev Neurol.* 2013;9(1):44-53.
- 773 3. Veleri S, Lazar CH, Chang B, Sieving PA, Banin E, and Swaroop A. Biology and therapy of inherited
774 retinal degenerative disease: insights from mouse models. *Dis Model Mech.* 2015;8(2):109-29.
- 775 4. Wright AF, Chakarova CF, Abd El-Aziz MM, and Bhattacharya SS. Photoreceptor degeneration: genetic
776 and mechanistic dissection of a complex trait. *Nat Rev Genet.* 2010;11(4):273-84.
- 777 5. Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, et al. Non-
778 syndromic retinitis pigmentosa. *Prog Retin Eye Res.* 2018;66:157-86.
- 779 6. Hanany M, Rivolta C, and Sharon D. Worldwide carrier frequency and genetic prevalence of autosomal
780 recessive inherited retinal diseases. *Proceedings of the National Academy of Sciences of the United States*
781 *of America.* 2020;117(5):2710-6.
- 782 7. Zelinger L, and Swaroop A. RNA Biology in Retinal Development and Disease. *Trends Genet.*
783 2018;34(5):341-51.
- 784 8. Farrar GJ, Carrigan M, Dockery A, Millington-Ward S, Palfi A, Chadderton N, et al. Toward an elucidation
785 of the molecular genetics of inherited retinal degenerations. *Human molecular genetics.* 2017;26(R1):R2-
786 R11.
- 787 9. Garafalo AV, Cideciyan AV, Heon E, Sheplock R, Pearson A, WeiYang Yu C, et al. Progress in treating
788 inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives.
789 *Prog Retin Eye Res.* 2020;77:100827.
- 790 10. Pierce EA, and Bennett J. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. *Cold Spring*
791 *Harb Perspect Med.* 2015;5(9):a017285.
- 792 11. Gardiner KL, Cideciyan AV, Swider M, Dufour VL, Sumaroka A, Komaromy AM, et al. Long-Term
793 Structural Outcomes of Late-Stage RPE65 Gene Therapy. *Mol Ther.* 2020;28(1):266-78.

- 794 12. Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, et al.
795 Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. *Nat Rev Drug Discov.*
796 2020;19(2):93-111.
- 797 13. Scholl HP, Strauss RW, Singh MS, Dalkara D, Roska B, Picaud S, et al. Emerging therapies for inherited
798 retinal degeneration. *Sci Transl Med.* 2016;8(368):368rv6.
- 799 14. Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, et al. Screening out irrelevant cell-based
800 models of disease. *Nat Rev Drug Discov.* 2016;15(11):751-69.
- 801 15. Cremers FPM, Boon CJF, Bujakowska K, and Zeitz C. Special Issue Introduction: Inherited Retinal
802 Disease: Novel Candidate Genes, Genotype-Phenotype Correlations, and Inheritance Models. *Genes.*
803 2018;9(4).
- 804 16. den Hollander AI, Roepman R, Koenekoop RK, and Cremers FP. Leber congenital amaurosis: genes,
805 proteins and disease mechanisms. *Prog Retin Eye Res.* 2008;27(4):391-419.
- 806 17. Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, et al. The centrosomal protein
807 nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. *Nature genetics.*
808 2006;38(6):674-81.
- 809 18. Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, et al. Mutations in CEP290,
810 which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nature genetics.*
811 2006;38(6):623-5.
- 812 19. McEwen DP, Koenekoop RK, Khanna H, Jenkins PM, Lopez I, Swaroop A, et al. Hypomorphic
813 CEP290/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory
814 sensory neurons. *Proceedings of the National Academy of Sciences of the United States of America.*
815 2007;104(40):15917-22.
- 816 20. Coppieters F, Lefever S, Leroy BP, and De Baere E. CEP290, a gene with many faces: mutation overview
817 and presentation of CEP290base. *Human mutation.* 2010;31(10):1097-108.
- 818 21. Drivas TG, Wojno AP, Tucker BA, Stone EM, and Bennett J. Basal exon skipping and genetic pleiotropy:
819 A predictive model of disease pathogenesis. *Sci Transl Med.* 2015;7(291):291ra97.

- 820 22. Craige B, Tsao CC, Diener DR, Hou Y, Lechtreck KF, Rosenbaum JL, et al. CEP290 tethers flagellar
821 transition zone microtubules to the membrane and regulates flagellar protein content. *J Cell Biol.*
822 2010;190(5):927-40.
- 823 23. Rachel RA, Li T, and Swaroop A. Photoreceptor sensory cilia and ciliopathies: focus on CEP290, RPGR
824 and their interacting proteins. *Cilia.* 2012;1(1):22.
- 825 24. Drivas TG, Holzbaaur EL, and Bennett J. Disruption of CEP290 microtubule/membrane-binding domains
826 causes retinal degeneration. *J Clin Invest.* 2013;123(10):4525-39.
- 827 25. Chang B, Khanna H, Hawes N, Jimeno D, He S, Lillo C, et al. In-frame deletion in a novel
828 centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset
829 retinal degeneration in the rd16 mouse. *Human molecular genetics.* 2006;15(11):1847-57.
- 830 26. Rachel RA, Yamamoto EA, Dewanjee MK, May-Simera HL, Sergeev YV, Hackett AN, et al. CEP290
831 alleles in mice disrupt tissue-specific cilia biogenesis and recapitulate features of syndromic ciliopathies.
832 *Human molecular genetics.* 2015;24(13):3775-91.
- 833 27. Tsang WY, Bossard C, Khanna H, Peranen J, Swaroop A, Malhotra V, et al. CP110 suppresses primary
834 cilia formation through its interaction with CEP290, a protein deficient in human ciliary disease.
835 *Developmental cell.* 2008;15(2):187-97.
- 836 28. Barbelanne M, Hossain D, Chan DP, Peranen J, and Tsang WY. Nephrocystin proteins NPHP5 and Cep290
837 regulate BBSome integrity, ciliary trafficking and cargo delivery. *Human molecular genetics.*
838 2015;24(8):2185-200.
- 839 29. Wu Z, Pang N, Zhang Y, Chen H, Peng Y, Fu J, et al. CEP290 is essential for the initiation of ciliary
840 transition zone assembly. *PLoS Biol.* 2020;18(12):e3001034.
- 841 30. Prosser SL, Tkach J, Gheiratmand L, Kim J, Raught B, Morrison CG, et al. Aggresome assembly at the
842 centrosome is driven by CP110-CEP97-CEP290 and centriolar satellites. *Nat Cell Biol.* 2022;24(4):483-96.
- 843 31. den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, et al. Mutations in the
844 CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet.*
845 2006;79(3):556-61.

- 846 32. Cideciyan AV, Aleman TS, Jacobson SG, Khanna H, Sumaroka A, Aguirre GK, et al. Centrosomal-ciliary
847 gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual
848 brain: implications for therapy of Leber congenital amaurosis. *Human mutation*. 2007;28(11):1074-83.
- 849 33. Shimada H, Lu Q, Insinna-Kettenhofen C, Nagashima K, English MA, Semler EM, et al. In Vitro Modeling
850 Using Ciliopathy-Patient-Derived Cells Reveals Distinct Cilia Dysfunctions Caused by CEP290 Mutations.
851 *Cell reports*. 2017;20(2):384-96.
- 852 34. Leroy BP, Birch DG, Duncan JL, Lam BL, Koenekoop RK, Porto FBO, et al. LEBER CONGENITAL
853 AMAUROSIS DUE TO CEP290 MUTATIONS-SEVERE VISION IMPAIRMENT WITH A HIGH
854 UNMET MEDICAL NEED: A Review. *Retina*. 2021;41(5):898-907.
- 855 35. Cideciyan AV, Rachel RA, Aleman TS, Swider M, Schwartz SB, Sumaroka A, et al. Cone photoreceptors
856 are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an
857 all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. *Human molecular genetics*.
858 2011;20(7):1411-23.
- 859 36. Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, and Cremers FP.
860 Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent
861 Mutation in CEP290. *Mol Ther Nucleic Acids*. 2012;1:e14.
- 862 37. Gerard X, Perrault I, Hanein S, Silva E, Bigot K, Defoort-Delhemmes S, et al. AON-mediated Exon
863 Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290
864 Mutation. *Mol Ther Nucleic Acids*. 2012;1:e29.
- 865 38. Burnight ER, Wiley LA, Drack AV, Braun TA, Anfinson KR, Kaalberg EE, et al. CEP290 gene transfer
866 rescues Leber congenital amaurosis cellular phenotype. *Gene Ther*. 2014;21(7):662-72.
- 867 39. Dooley SJ, McDougald DS, Fisher KJ, Bennicelli JL, Mitchell LG, and Bennett J. Spliceosome-Mediated
868 Pre-mRNA trans-Splicing Can Repair CEP290 mRNA. *Mol Ther Nucleic Acids*. 2018;12:294-308.
- 869 40. Dulla K, Aguila M, Lane A, Jovanovic K, Parfitt DA, Schulkens I, et al. Splice-Modulating
870 Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10
871 Models. *Mol Ther Nucleic Acids*. 2018;12:730-40.
- 872 41. Kim YJ, Kim S, Jung Y, Jung E, Kwon HJ, and Kim J. Eupatilin rescues ciliary transition zone defects to
873 ameliorate ciliopathy-related phenotypes. *J Clin Invest*. 2018;128(8):3642-8.

- 874 42. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, Sekiguchi K, et al. Self-formation of optic cups
875 and storable stratified neural retina from human ESCs. *Cell Stem Cell*. 2012;10(6):771-85.
- 876 43. Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. *Cell Stem*
877 *Cell*. 2013;12(5):520-30.
- 878 44. Welsbie DS, Mitchell KL, Jaskula-Ranga V, Sluch VM, Yang Z, Kim J, et al. Enhanced Functional
879 Genomic Screening Identifies Novel Mediators of Dual Leucine Zipper Kinase-Dependent Injury Signaling
880 in Neurons. *Neuron*. 2017;94(6):1142-54 e6.
- 881 45. Zhong X, Gutierrez C, Xue T, Hampton C, Vergara MN, Cao LH, et al. Generation of three-dimensional
882 retinal tissue with functional photoreceptors from human iPSCs. *Nat Commun*. 2014;5:4047.
- 883 46. Capowski EE, Samimi K, Mayerl SJ, Phillips MJ, Pinilla I, Howden SE, et al. Reproducibility and staging
884 of 3D human retinal organoids across multiple pluripotent stem cell lines. *Development*. 2019;146(1).
- 885 47. Kaya KD, Chen HY, Brooks MJ, Kelley RA, Shimada H, Nagashima K, et al. Transcriptome-based
886 molecular staging of human stem cell-derived retinal organoids uncovers accelerated photoreceptor
887 differentiation by 9-cis retinal. *Molecular vision*. 2019;25:663-78.
- 888 48. Regent F, Batz Z, Kelley RA, Gieser L, Swaroop A, Chen HY, et al. Nicotinamide Promotes Formation of
889 Retinal Organoids From Human Pluripotent Stem Cells via Enhanced Neural Cell Fate Commitment. *Front*
890 *Cell Neurosci*. 2022;16:878351.
- 891 49. Saha A, Capowski E, Fernandez Zepeda MA, Nelson EC, Gamm DM, and Sinha R. Cone photoreceptors in
892 human stem cell-derived retinal organoids demonstrate intrinsic light responses that mimic those of primate
893 fovea. *Cell Stem Cell*. 2022;29(3):460-71 e3.
- 894 50. Cowan CS, Renner M, De Gennaro M, Gross-Scherf B, Goldblum D, Hou Y, et al. Cell Types of the
895 Human Retina and Its Organoids at Single-Cell Resolution. *Cell*. 2020;182(6):1623-40 e34.
- 896 51. Sridhar A, Hoshino A, Finkbeiner CR, Chitsazan A, Dai L, Haugan AK, et al. Single-Cell Transcriptomic
897 Comparison of Human Fetal Retina, hPSC-Derived Retinal Organoids, and Long-Term Retinal Cultures.
898 *Cell reports*. 2020;30(5):1644-59 e4.
- 899 52. Bell CM, Zack DJ, and Berlinicke CA. Human Organoids for the Study of Retinal Development and
900 Disease. *Annu Rev Vis Sci*. 2020;6:91-114.

- 901 53. Kruczek K, and Swaroop A. Pluripotent stem cell-derived retinal organoids for disease modeling and
902 development of therapies. *Stem Cells*. 2020;38(10):1206-15.
- 903 54. Struzyna LA, and Watt ML. The Emerging Role of Neuronal Organoid Models in Drug Discovery:
904 Potential Applications and Hurdles to Implementation. *Mol Pharmacol*. 2021;99(4):256-65.
- 905 55. Chen HY, Kaya KD, Dong L, and Swaroop A. Three-dimensional retinal organoids from mouse pluripotent
906 stem cells mimic in vivo development with enhanced stratification and rod photoreceptor differentiation.
907 *Molecular vision*. 2016;22:1077-94.
- 908 56. DiStefano T, Chen HY, Panebianco C, Kaya KD, Brooks MJ, Gieser L, et al. Accelerated and Improved
909 Differentiation of Retinal Organoids from Pluripotent Stem Cells in Rotating-Wall Vessel Bioreactors.
910 *Stem Cell Reports*. 2018;10(1):300-13.
- 911 57. Armitage SG, Greenberg PD, Olsen AL, Pearl D, and Vander Kamp H. The effects of reserpine on
912 schizophrenic patients. *AMA Arch Neurol Psychiatry*. 1956;76(2):198-204.
- 913 58. Kalliomaki JL, and Kasanen A. A new combination of hypotensive drugs (reserpine, dihydralazine,
914 furosemide and triamterene) for the treatment of arterial hypertension without risk of hypotassaemia.
915 *Curr Ther Res Clin Exp*. 1969;11(6):344-50.
- 916 59. Bernstein AI, Stout KA, and Miller GW. The vesicular monoamine transporter 2: an underexplored
917 pharmacological target. *Neurochem Int*. 2014;73:89-97.
- 918 60. Lee KI, Kim MJ, Koh H, Lee JI, Namkoong S, Oh WK, et al. The anti-hypertensive drug reserpine induces
919 neuronal cell death through inhibition of autophagic flux. *Biochem Biophys Res Commun*.
920 2015;462(4):402-8.
- 921 61. Kim YC, and Guan KL. mTOR: a pharmacologic target for autophagy regulation. *J Clin Invest*.
922 2015;125(1):25-32.
- 923 62. Jayaraj GG, Hipp MS, and Hartl FU. Functional Modules of the Proteostasis Network. *Cold Spring Harb*
924 *Perspect Biol*. 2020;12(1).
- 925 63. Klaipts CL, Jayaraj GG, and Hartl FU. Pathways of cellular proteostasis in aging and disease. *J Cell Biol*.
926 2018;217(1):51-63.
- 927 64. Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, and Kroemer G. Pharmacological modulation of
928 autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov*. 2017;16(7):487-511.

- 929 65. Jones TM, Espitia C, Wang W, Nawrocki ST, and Carew JS. Moving beyond hydroxychloroquine: the
930 novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies. *Cancer*
931 *Commun (Lond)*. 2019;39(1):72.
- 932 66. Mizushima N. Autophagy: process and function. *Genes & development*. 2007;21(22):2861-73.
- 933 67. Bresciani A, Spiezia MC, Boggio R, Cariulo C, Nordheim A, Altobelli R, et al. Quantifying autophagy
934 using novel LC3B and p62 TR-FRET assays. *PloS one*. 2018;13(3):e0194423.
- 935 68. Kumar AV, Mills J, and Lapierre LR. Selective Autophagy Receptor p62/SQSTM1, a Pivotal Player in
936 Stress and Aging. *Front Cell Dev Biol*. 2022;10:793328.
- 937 69. Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, et al. p62 links the autophagy pathway and the
938 ubiquitin-proteasome system upon ubiquitinated protein degradation. *Cell Mol Biol Lett*. 2016;21:29.
- 939 70. Pampliega O, Orhon I, Patel B, Sridhar S, Diaz-Carretero A, Beau I, et al. Functional interaction between
940 autophagy and ciliogenesis. *Nature*. 2013;502(7470):194-200.
- 941 71. Tang Z, Lin MG, Stowe TR, Chen S, Zhu M, Stearns T, et al. Autophagy promotes primary ciliogenesis by
942 removing OFD1 from centriolar satellites. *Nature*. 2013;502(7470):254-7.
- 943 72. Yamamoto Y, and Mizushima N. Autophagy and Ciliogenesis. *JMA J*. 2021;4(3):207-15.
- 944 73. Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, and Cuendet M. HDAC6 as a target for
945 neurodegenerative diseases: what makes it different from the other HDACs? *Mol Neurodegener*. 2013;8:7.
- 946 74. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, and Golemis EA. HEF1-dependent Aurora A
947 activation induces disassembly of the primary cilium. *Cell*. 2007;129(7):1351-63.
- 948 75. Michalska-Malecka K, Kabiesz A, Kimsa MW, Strzalka-Mrozik B, Forminska-Kapuscik M, Nita M, et al.
949 Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related
950 macular degeneration. *Clin Interv Aging*. 2016;11:357-65.
- 951 76. Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I, et al. The effect of
952 intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related
953 macular degeneration. *Ophthalmologica*. 2009;223(6):383-9.
- 954 77. Calvo CM, Sridhar J, Shahlaee A, and Ho AC. Reduction of Diabetic Macular Edema in the Untreated
955 Fellow Eye Following Intravitreal Injection of Aflibercept. *Ophthalmic Surg Lasers Imaging Retina*.
956 2016;47(5):474-6.

- 957 78. Zlotcavitch L, Flynn HW, Jr., Avery RL, and Rachitskaya A. Progression to macula-off tractional retinal
958 detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic
959 retinopathy. *Clin Ophthalmol.* 2015;9:69-71.
- 960 79. Rotsos T, Symeonidis C, Triantafillopoulou I, Kanellopoulos S, and Kouris A. Significant reduction of
961 diabetic macular edema following intravitreal ranibizumab injection in the fellow eye. *Int Ophthalmol.*
962 2014;34(6):1271-4.
- 963 80. Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: Misconceptions,
964 challenges, and opportunities for academic researchers. *Sci Transl Med.* 2021;13(612):eabd5524.
- 965 81. Engle SJ, and Puppala D. Integrating human pluripotent stem cells into drug development. *Cell Stem Cell.*
966 2013;12(6):669-77.
- 967 82. Vergara MN, Flores-Bellver M, Aparicio-Domingo S, McNally M, Wahlin KJ, Saxena MT, et al. Three-
968 dimensional automated reporter quantification (3D-ARQ) technology enables quantitative screening in
969 retinal organoids. *Development.* 2017;144(20):3698-705.
- 970 83. Zhang L, Chen C, Fu J, Lilley B, Berlinicke C, Hansen B, et al. Large-scale phenotypic drug screen
971 identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. *eLife.* 2021;10.
- 972 84. Kost-Alimova M, Sidhom EH, Satyam A, Chamberlain BT, Dvela-Levitt M, Melanson M, et al. A High-
973 Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid
974 Repurposing for Acute Lung Injury. *Cell Rep Med.* 2020;1(8):100137.
- 975 85. Mills RJ, Parker BL, Quaiife-Ryan GA, Voges HK, Needham EJ, Bornot A, et al. Drug Screening in
976 Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate
977 Pathway. *Cell Stem Cell.* 2019;24(6):895-907 e6.
- 978 86. Chen Y, Palczewska G, Masuho I, Gao S, Jin H, Dong Z, et al. Synergistically acting agonists and
979 antagonists of G protein-coupled receptors prevent photoreceptor cell degeneration. *Science signaling.*
980 2016;9(438):ra74.
- 981 87. Yohn CN, Gergues MM, and Samuels BA. The role of 5-HT receptors in depression. *Mol Brain.*
982 2017;10(1):28.
- 983 88. Iggo A, and Vogt M. Preganglionic sympathetic activity in normal and in reserpine-treated cats. *J Physiol.*
984 1960;150:114-33.

- 985 89. Cheung MP, M.: StatPearls; 2022.
- 986 90. Kruiswijk F, Labuschagne CF, and Vousden KH. p53 in survival, death and metabolic health: a lifeguard
987 with a licence to kill. *Nature reviews Molecular cell biology*. 2015;16(7):393-405.
- 988 91. Liu Y, Leslie PL, and Zhang Y. Life and Death Decision-Making by p53 and Implications for Cancer
989 Immunotherapy. *Trends Cancer*. 2021;7(3):226-39.
- 990 92. Wylie A, Jones AE, Das S, Lu WJ, and Abrams JM. Distinct p53 isoforms code for opposing
991 transcriptional outcomes. *Developmental cell*. 2022.
- 992 93. Venkatesh A, Ma S, Le YZ, Hall MN, Ruegg MA, and Punzo C. Activated mTORC1 promotes long-term
993 cone survival in retinitis pigmentosa mice. *J Clin Invest*. 2015;125(4):1446-58.
- 994 94. Venkatesh A, Ma S, and Punzo C. TSC but not PTEN loss in starving cones of retinitis pigmentosa mice
995 leads to an autophagy defect and mTORC1 dissociation from the lysosome. *Cell Death Dis*.
996 2016;7(6):e2279.
- 997 95. Tomita Y, Qiu C, Bull E, Allen W, Kotoda Y, Talukdar S, et al. Muller glial responses compensate for
998 degenerating photoreceptors in retinitis pigmentosa. *Experimental & molecular medicine*.
999 2021;53(11):1748-58.
- 1000 96. Palko SI, Saba NJ, Mullane E, Nicholas BD, Nagasaka Y, Ambati J, et al. Compartmentalized citrullination
1001 in Muller glial endfeet during retinal degeneration. *Proceedings of the National Academy of Sciences of the*
1002 *United States of America*. 2022;119(9).
- 1003 97. Ferraro S, Gomez-Montalvo AI, Olmos R, Ramirez M, and Lamas M. Primary cilia in rat mature Muller
1004 glia: downregulation of IFT20 expression reduces sonic hedgehog-mediated proliferation and
1005 dedifferentiation potential of Muller glia primary cultures. *Cell Mol Neurobiol*. 2015;35(4):533-42.
- 1006 98. Deleyto-Seldas N, and Efeyan A. The mTOR-Autophagy Axis and the Control of Metabolism. *Front Cell*
1007 *Dev Biol*. 2021;9:655731.
- 1008 99. Villarejo-Zori B, Jimenez-Loygorri JI, Zapata-Munoz J, Bell K, and Boya P. New insights into the role of
1009 autophagy in retinal and eye diseases. *Mol Aspects Med*. 2021;82:101038.
- 1010 100. Chang KC, Liu PF, Chang CH, Lin YC, Chen YJ, and Shu CW. The interplay of autophagy and oxidative
1011 stress in the pathogenesis and therapy of retinal degenerative diseases. *Cell Biosci*. 2022;12(1):1.

- 1012 101. Vucicevic L, Misirkic-Marjanovic M, Harhaji-Trajkovic L, Maric N, and Trajkovic V. Mechanisms and
1013 therapeutic significance of autophagy modulation by antipsychotic drugs. *Cell Stress*. 2018;2(11):282-91.
- 1014 102. Zhou Z, Doggett TA, Sene A, Apte RS, and Ferguson TA. Autophagy supports survival and
1015 phototransduction protein levels in rod photoreceptors. *Cell Death Differ*. 2015;22(3):488-98.
- 1016 103. Yao J, Jia L, Feathers K, Lin C, Khan NW, Klionsky DJ, et al. Autophagy-mediated catabolism of visual
1017 transduction proteins prevents retinal degeneration. *Autophagy*. 2016;12(12):2439-50.
- 1018 104. Qiu Y, Yao J, Jia L, Thompson DA, and Zacks DN. Shifting the balance of autophagy and proteasome
1019 activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor
1020 homeostasis. *Cell Death Dis*. 2019;10(8):547.
- 1021 105. Hargrove-Grimes P, Mondal AK, Gumerson J, Nellissery J, Aponte AM, Gieser L, et al. Loss of
1022 endocytosis-associated RabGEF1 causes aberrant morphogenesis and altered autophagy in photoreceptors
1023 leading to retinal degeneration. *PLoS genetics*. 2020;16(12):e1009259.
- 1024 106. Mockel A, Obringer C, Hakvoort TB, Seeliger M, Lamers WH, Stoetzel C, et al. Pharmacological
1025 modulation of the retinal unfolded protein response in Bardet-Biedl syndrome reduces apoptosis and
1026 preserves light detection ability. *J Biol Chem*. 2012;287(44):37483-94.
- 1027 107. Zaninello M, Palikaras K, Naon D, Iwata K, Herkenne S, Quintana-Cabrera R, et al. Inhibition of
1028 autophagy curtails visual loss in a model of autosomal dominant optic atrophy. *Nat Commun*.
1029 2020;11(1):4029.
- 1030 108. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al. HDAC6 controls autophagosome
1031 maturation essential for ubiquitin-selective quality-control autophagy. *EMBO J*. 2010;29(5):969-80.
- 1032 109. Chang P, Li H, Hu H, Li Y, and Wang T. The Role of HDAC6 in Autophagy and NLRP3 Inflammasome.
1033 *Front Immunol*. 2021;12:763831.
- 1034 110. Toulis V, Garcia-Monclus S, de la Pena-Ramirez C, Arenas-Galnares R, Abril JF, Todi SV, et al. The
1035 Deubiquitinating Enzyme Ataxin-3 Regulates Ciliogenesis and Phagocytosis in the Retina. *Cell reports*.
1036 2020;33(6):108360.
- 1037 111. Faber S, and Roepman R. Balancing the Photoreceptor Proteome: Proteostasis Network Therapeutics for
1038 Inherited Retinal Disease. *Genes*. 2019;10(8).

- 1039 112. Chen HY, Kelley RA, and Swaroop A. HIPRO: A High-Efficiency, Hypoxia-Induced Protocol for
1040 Generation of Photoreceptors in Retinal Organoids from Mouse Pluripotent Stem Cells. *STAR Protoc.*
1041 2020;1(1).
- 1042 113. Kelley RA, Chen HY, Swaroop A, and Li T. Accelerated Development of Rod Photoreceptors in Retinal
1043 Organoids Derived from Human Pluripotent Stem Cells by Supplementation with 9-cis Retinal. *STAR*
1044 *Protoc.* 2020;1(1).
- 1045 114. Regent F, Chen HY, Kelley RA, Qu Z, Swaroop A, and Li T. A simple and efficient method for generating
1046 human retinal organoids. *Molecular vision.* 2020;26:97-105.
- 1047 115. Kim JW, Yang HJ, Brooks MJ, Zelinger L, Karakulah G, Gotoh N, et al. NRL-Regulated Transcriptome
1048 Dynamics of Developing Rod Photoreceptors. *Cell reports.* 2016;17(9):2460-73.
- 1049 116. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape
1050 plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics*
1051 *(Oxford, England).* 2009;25(8):1091-3.
- 1052 117. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021:
1053 customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement
1054 sets. *Nucleic acids research.* 2021;49(D1):D605-D12.
- 1055 118. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for
1056 functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic acids research.*
1057 2019;47(W1):W191-W8.
- 1058 119. Wang Y, Jadhav A, Southal N, Huang R, and Nguyen DT. A grid algorithm for high throughput fitting of
1059 dose-response curve data. *Curr Chem Genomics.* 2010;4:57-66.

1060

1061

1062 **FIGURE LEGENDS**

1063 **Fig. 1. Drug discovery pipelines to identify drug candidates.**

1064 (A) Morphology of *Nrl*-GFP wild type (WT) and *rd16* retinal organoids differentiated from
1065 mouse induced pluripotent stem cells (iPSC) at various differentiation time points. (B) Flow
1066 cytometry analysis of GFP+ rod photoreceptors at different developmental stages. *, $p < 0.05$; **, $p < 0.01$. Each data point summarized at least 3 batches of independent experiments, each of
1067 which included at least 10 organoids. (C) Fluorescent images of dissociated day (D) 28 WT and
1068 *rd16* cells stained by 4',6-diamidino-2-phenylindole (DAPI) and anti-GFP antibody. (D)
1069 Schematic outline of the drug discovery strategy.

1071 **Fig. 2. Identification of reserpine as the lead compound.**

1072 (A) Timeline for hit validation in *rd16* retinal organoids. (B) Immunostaining of rod cell marker
1073 rhodopsin (RHO, green) and cone cell marker S-opsin (OPN1SW, red) in wild-type (WT) and
1074 *rd16* organoids treated with non-toxic positive hits (B01-B05). Drug vehicle dimethylsulfoxide
1075 (DMSO) was used as control. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI).
1076 Arrowheads indicate relevant staining. Images were representative of at least 3 independent
1077 experiments, each of which had at least 3 organoids. (C) Bee swarm plots showing the
1078 quantification of fluorescence intensity of rhodopsin (upper) and S-opsin (lower) staining in the
1079 validation. The shape of the plot indicates the distribution of data points, which are shown by
1080 colorful circles in the center. The black diamond indicates the mean, and the error bar reveals
1081 standard deviation. The pink dash line shows the mean fluorescence intensity of DMSO-treated
1082 organoids. The plot summarizes at least 3 independent experiments with at least 3 organoids in
1083 each batch. *, $p < 0.05$; **, $p < 0.01$. (D) Chemical structure depiction of the selected lead
1084 compound reserpine.

1085 **Fig. 3. Effect of reserpine (RSP) on *LCA10* patient retinal organoids.**

1086 (A) Timeline for RSP treatments and harvest of patient organoids. (B) Immunostaining of
1087 rhodopsin (RHO, green) and ARL13B (red) as well as S-opsin (OPN1SW, green) and L/M-opsin
1088 (OPN1LMW, red). Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads
1089 indicate relevant staining. Images were representative of at least 3 independent experiments, each
1090 of which had at least 3 organoids. (C) Transmission electron microscopy analysis of control,
1091 untreated and treated patient organoids. Arrowheads indicate relevant staining. (D)
1092 Quantification of the number of the ciliary vesicles, elongated ciliary axoneme and aberrant cilia
1093 (left) as well as the length of the primary cilia (right) in untreated and RSP-treated patient
1094 organoids. Aberrant cilia were defined as docked mother centrioles without ciliary vesicles or
1095 elongated ciliary axoneme. The data summarized at least 4 batches of independent experiments,
1096 each of which has at least 2 organoids and 7 docked mother centrioles. The shape of the bee
1097 swamp plot indicates the distribution of data points, which are shown by colorful circles in the
1098 center. The black diamond indicates the mean, and the error bar reveals standard deviation. *,
1099 $p < 0.05$.

1100 **Fig. 4. Transcriptomic upregulation of proteasomal components induced by reserpine in**
1101 **patient retinal organoids.**

1102 (A) PCA diagram of patient and control organoids shows altered retinal transcriptomes after
1103 reserpine treatment. (B) Drug-induced genes in patient organoids displayed specific trends
1104 compared to control organoids. (C) Volcano plot summarizes reserpine induced differential gene
1105 expression changes in LCA-1 organoids. (D) ClueGO analysis of KEGG pathway enrichment
1106 shows overexpressed genes mapping to protein homeostasis, metabolism and cellular signaling
1107 processes. The red rectangle highlights the “Proteasome” factor. (E) GSEA plot showing

1108 enrichment and significance of Proteostasis Network. (F) Histogram of log fold change of the
1109 Proteostasis Network genes upon reserpine treatment. (G) Proteasomal subunits responding
1110 strongly to reserpine treatment. (H) *SQSTM1* (p62) and *NFE2L2* (NRF2), two key regulators of
1111 protein homeostasis, showed increased expression after reserpine treatment.

1112 **Fig. 5. Proteostasis Network in patient organoid cultures in response to reserpine**
1113 **treatment.**

1114 (A) Schematic diagram of autophagy. (B) Immunoblot analyses and quantification of autophagy
1115 cargo adaptor p62 and autophagosome marker LC-II in control and patient organoids treated
1116 with reserpine (RSP). (C) Schematic diagram showing the proteome balance between ubiquitin-
1117 proteasome system (UPS) and autophagy is mediated through p62 as documented in the
1118 literature. (D) Immunoblot analysis of the 20S proteasome in control, DMSO-, and RSP-treated
1119 cultures. β -Actin was used as the loading control. (E) Proteasomal chymotrypsin-like activity in
1120 organoids. (F) Immunoblot analyses and quantification of key regulators of cilium
1121 assembly/disassembly in control, untreated and RSP-treated patient organoids. The drug vehicle
1122 dimethylsulfoxide (DMSO) was added to the cultures in the untreated group at the same volume
1123 as the drugs. β -Actin was used as the loading control. The histograms summarize data in at least
1124 3 batches of experiments, each of which had at least 3 retinal organoids per group. Each dot in
1125 the histogram shows data in one batch of experiment and are presented as mean \pm standard
1126 deviation. *, $p < 0.05$; ***, $p < 0.005$.

1127 **Fig. 6. Intravitreal injection of reserpine (RSP) into *rd16* mice.**

1128 (A) Timeline of *in vivo* intravitreal injection. The eyes used for subsequent analyses were
1129 highlighted by red rectangles. (B) Immunostaining of DMSO- and RSP-treated *rd16* retina (left)
1130 and quantification of the GFP+ outer nuclear layer (ONL) thickness (right). The shape of the bee

1131 swamp plot indicates the distribution of data points, which are shown by colorful circles in the
1132 center. The black diamond indicates the mean, and the error bar reveals standard deviation. *,
1133 $p < 0.05$. (C) Immunostaining of outer segment (OS) axoneme marker RP1 (magenta, upper) and
1134 ciliary rootlet marker Rootletin (magenta, lower). (D) p62 level in DMSO- and RSP-treated
1135 photoreceptors shown by immunostaining. In (B), (C), and (D), nuclei were stained by 4',6-
1136 diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were
1137 representative of at least 3 mice from different litters. (E) Western blot analysis of 20S
1138 proteasome in wild type (WT), DMSO-, and RSP-treated retina of *rd16* mice. γ -Tubulin was
1139 used as the loading control. (F) Proteasomal chymotrypsin-like activity in *rd16* retina. Data in
1140 the histogram were summarized from at least 3 mice from different litters and are presented as
1141 mean \pm standard deviation. *, $p < 0.05$.

1142 **Fig. 7. Action mechanisms of reserpine in photoreceptor survival.**

1143 *CEP290* mutations lead to defects in the outer segment biogenesis and consequently ciliary
1144 vesicles carrying building blocks of the primary cilium and ciliary proteins are accumulated in
1145 patient photoreceptors, leading to the activation of autophagy to degrade unwanted materials. As
1146 an autophagy inhibitor, reserpine downregulates autophagy and increases p62 level in
1147 photoreceptors. As p62 is a mediator and cargo adaptor of ubiquitin-proteasome system and
1148 autophagy, upregulation of p62 not only activates the 20S proteasome to facilitate the clearance
1149 of the accumulated autophagosome but also facilitates the degradation of histone deacetylase 6
1150 (HDAC6), which deacetylates microtubules. Removal of HDAC6 in photoreceptors thus should
1151 improve the stability of intracellular microtubule and facilitate the transport of pre-ciliary
1152 vesicles to the mother centriole for outer segment biogenesis.

1153 **Fig. 7. Action mechanisms of reserpine in photoreceptor survival.**

1154 *CEP290* mutations lead to defects in the outer segment biogenesis and consequently ciliary
1155 vesicles carrying building blocks of the primary cilium and ciliary proteins are accumulated in
1156 patient photoreceptors, leading to the activation of autophagy to degrade unwanted materials. As
1157 an autophagy inhibitor, reserpine downregulates autophagy and increases p62 level in
1158 photoreceptors. As p62 is a mediator and cargo adaptor of ubiquitin-proteasome system and
1159 autophagy, upregulation of p62 not only activates the 20S proteasome to facilitate the clearance
1160 of the accumulated autophagosome but also facilitates the degradation of histone deacetylase 6
1161 (HDAC6), which deacetylates microtubules. Removal of HDAC6 in photoreceptors thus should
1162 improve the stability of intracellular microtubule and facilitate the transport of pre-ciliary
1163 vesicles to the mother centriole for outer segment biogenesis.

1164

1165

1166 **Source Data Files - Legends**

1167 **Fig. 5. Source data 1. Overlay of the brightfield and chemiluminescence images indicating**
1168 **the signal of p62.** RSP stands for reserpine. The size of the protein ladders, p62, and relevant
1169 sample identity are labeled.

1170 **Fig. 5. Source data 2. Overlay of the brightfield and chemiluminescence images indicating**
1171 **the signal of LC3.** RSP stands for reserpine. The size of the protein ladders, LC3, and relevant
1172 sample identity are labeled.

1173 **Fig. 5. Source data 3. Overlay of the brightfield and chemiluminescence images indicating**
1174 **the signal of β -Actin.** RSP stands for reserpine. The size of the protein ladders, β -Actin, and
1175 relevant sample identity are labeled.

1176 **Fig. 5. Source data 4. Overlay of the brightfield and chemiluminescence images indicating**
1177 **the signal of 20s proteasome and β -Actin.** RSP stands for reserpine. The size of the protein
1178 ladders, β -Actin, 20s proteasome, and relevant sample identity are labeled.

1179 **Fig. 5. Source data 5. Overlay of the brightfield and chemiluminescence images indicating**
1180 **the signal of IFT88.** RSP stands for reserpine. The size of the protein ladders, IFT88, and
1181 relevant sample identity are labeled.

1182 **Fig. 5. Source data 6. Overlay of the brightfield and chemiluminescence images indicating**
1183 **the signal of BBS6.** RSP stands for reserpine. The size of the protein ladders, BBS6, and
1184 relevant sample identity are labeled.

1185 **Fig. 5. Source data 7. Overlay of the brightfield and chemiluminescence images indicating**
1186 **the signal of CEP164.** RSP stands for reserpine. The size of the protein ladders, CEP164, and
1187 relevant sample identity are labeled.

1188 **Fig. 5. Source data 8. Overlay of the brightfield and chemiluminescence images indicating**
1189 **the signal of OFD1.** RSP stands for reserpine. The size of the protein ladders, OFD1, and
1190 relevant sample identity are labeled.

1191 **Fig. 5. Source data 9. Overlay of the brightfield and chemiluminescence images indicating**
1192 **the signal of HDAC6.** RSP stands for reserpine. The size of the protein ladders, HDAC6, and
1193 relevant sample identity are labeled.

1194 **Fig. 5. Source data 10. Overlay of the brightfield and chemiluminescence images indicating**
1195 **the signal of β -Actin.** RSP stands for reserpine. The size of the protein ladders, β -Actin, and
1196 relevant sample identity are labeled.

1197 **Fig. 6. Source data 1. Overlay of the brightfield and chemiluminescence images indicating**
1198 **the signal of 20s proteasome.** WT and RSP stand for wild type and reserpine respectively. The
1199 size of the protein ladders, 20s proteasome, and relevant sample identity are labeled.

1200 **Fig. 6. Source data 2. Overlay of the brightfield and chemiluminescence images indicating**
1201 **the signal of γ -Tubulin.** WT and RSP stand for wild type and reserpine respectively. The size of
1202 the protein ladders, γ -Tubulin, and relevant sample identity are labeled.

1203 **Fig. S2. Source data 1. Overlay of the brightfield and chemiluminescence images indicating**
1204 **the signal of CEP290.** The size of the protein ladders, CEP290, and relevant sample identity are
1205 labeled.

1206 **Fig. S2. Source data 2. Overlay of the brightfield and chemiluminescence images indicating**
1207 **the signal of GAPDH.** The size of the protein ladders, GAPGH, and relevant sample identity are
1208 labeled.

1209 **Fig. S5. Source data 1. Overlay of the brightfield and chemiluminescence images indicating**
1210 **the signal of LC3.** The size of the protein ladders, LC3, and relevant sample identity are labeled.

1211 **Fig. S5. Source data 2. Overlay of the brightfield and chemiluminescence images indicating**
1212 **the signal of p62.** The size of the protein ladders, p62, and relevant sample identity are labeled.

1213 **Fig. S5. Source data 3. Overlay of the brightfield and chemiluminescence images indicating**
1214 **the signal of β -actin.** The size of the protein ladders, β -Actin, and relevant sample identity are
1215 labeled.

1216

1217

1218









Fig. 2




A



B



C



D




Fig. 4





Fig 5







Fig. 7



Supplementary Materials and Methods

Mouse and human pluripotent cell lines

The mouse *Nrl*-GFP wild-type (WT) and rd16 induced pluripotent stem cell (iPSC) lines were reprogrammed from fibroblasts of day 14.5 mouse embryos as previously described (55). The generation and characterization of the familial control, LCA-1 and LCA-2 iPSC lines have been previously reported as well (33).

Animals

Cep290^{rd16/rd16} mice were obtained from the Jackson Labs and crossed to *Nrlp-EGFP* mice to generate *Nrlp-EGFP*; *Cep290*^{rd16/rd16} mice (referred to as *rd16*). The absence of the rd8 mutation in the colony was assessed by PCR. All animal procedures were approved by the Animal Care and Use committee of the National Eye Institutes (Animal study protocol NEI-650) and adhered to ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice were housed in an atmosphere-controlled environment (temperature: 22°C ± 2°C, humidity: 30%–70%), under a 12-hour dark/12-hour light cycle and supplied with food and water ad libitum. Food, water, and nesting material were changed weekly.

Compound libraries

We used three different small molecule libraries for our screening efforts. The library of 1,280 pharmacologically active compounds (LOPAC 1,280) consists of a collection of small molecules with characterized biological activities commonly used to test and validate screening assays. The library of U.S. Food and Drug Administration (FDA)-2800 approved drugs were set up internally. The compounds were first dissolved in 100% DMSO to generate a stock concentration with a final concentration of 10 mM and subsequently diluted into 7 concentrations and dispensed into 1536-well plates. The NCATS Mechanism Interrogation Plate (MIPE) 5.0 library

contains a collection of 1912 compounds (approved for clinical trials).

Maintenance of induced pluripotent stem cells

The WT and rd16 iPSC lines were maintained as previously described (*113*). Briefly, the iPSC lines were maintained on feeder cells (Millipore) in maintenance medium constituted by Knockout DMEM (ThermoFisher Scientific), 1x MEM non-essential amino acids (NEAA) (Sigma), 1x GlutaMAX (ThermoFisher Scientific), 1x Penicillin-Streptomycin (PS) (ThermoFisher Scientific), 2000 U/ml leukemia inhibitory factor (LIF) (Millipore), and 15% ES cell-qualified fetal bovine serum (FBS) (ThermoFisher Scientific) at 37°C, 5% CO₂. Full media change was performed every day, with 55 µM β-Mercaptoethanol (2-ME) (ThermoFisher Scientific) freshly added. Cells were passaged using TrypLE Express (ThermoFisher Scientific) every two days.

Human iPSC lines were maintained in Essential 8 (E8) (ThermoFisher Scientific) on growth factor-reduced (GFR) Matrigel (Corning)-coated plates, with media fully changed daily. Cells were maintained at 37°C, 5% O₂, 5% CO₂ and passaged at 60-80% confluency using the EDTA-based dissociation method (*114*).

Differentiation of mouse and human retinal organoids

The modified HIPRO protocol was used to differentiate mouse iPSCs into retinal organoids (*55, 113*). At differentiation day (D)0, iPSCs were plated in low adhesion U-shaped 96-well plate (Wako) at a density of 3000-5000 cells per well in 100 µl retinal differentiation medium consisting of GMEM (ThermoFisher Scientific), 1x NEAA, 1x sodium pyruvate (Sigma) and 1.5%(v/v) knockout serum replacement (KSR) (ThermoFisher Scientific). At D1, 240 µl GFR-Matrigel (>9.5 mg/ml) was diluted in 1.8 ml retinal differentiation medium and 20 µl diluent was aliquoted to each well of the 96-well plate. Retinal organoids from one 96-well plate were

transferred to a 100 mm poly(2-hydroxyethyl methacrylate) (Sigma)-coated petri dish with 12 ml DMEM/F12 with GlutaMAX, 1x N2 supplement and 1x PS. The media were replaced by DMEM/F12 with GlutaMAX, 1x PS, 1x N2 supplement, 1 mM taurine (Sigma), 500 nM 9-*cis* retinal (Sigma) and 100 ng/ml insulin-like growth factor 1 (IGF1) (ThermoFisher Scientific) at D10, and half-media change was performed every other day, with 55 μ M 2-ME freshly added to the media. From D26 and onward, 1x NEAA, 1x B27 supplement without Vitamin A (ThermoFisher Scientific) and 2%(v/v) FBS (ThermoFisher Scientific) were added to the culture. Half-media exchanges were performed every two days, with 55 μ M 2-ME freshly added to media. The cultures were incubated in 5% O₂ from D0 to D10 and in 20% O₂ from D10 onwards.

Human retinal organoid differentiation was performed as previously described (115). Briefly, small clumps dissociated from iPSCs in one well of a 6-well plate were resuspended in E8 medium supplemented with 10 μ M Y-27632 (Tocris) and transferred into one 100-mm polyHEMA-coated petri dish for embryoid body (EB) formation. Media were supplied with neural induction media (NIM) (DMEM/F-12 (1:1) (ThermoFisher Scientific), 1x N2 supplement, 1x NEAA, 2 μ g/ml heparin (Sigma) at D1 and D2 at a ratio of 3:1 and 1:1 respectively, and fully switched to NIM at D3. D7 EBs from one 100-mm petri dish were plated onto one GFR Matrigel-coated 60 mm dish and cultured in NIM, with media changed every 2-3 days. In the application requiring a large-scale production of retinal organoids, nicotinamide was added to the culture to reach a final concentration of 5 mM from D0 to D8 (48). NIM was replaced by 3:1 retinal induction medium (RIM) consisting of DMEM/F-12 supplemented with 1x B27 without Vitamin A (ThermoFisher Scientific), 1% antibiotic-antimycotic solution (ThermoFisher Scientific), 1% GlutaMAX and 1X NEAA at D16 and media change was performed every day until D28, on which the adherent cells were scraped off into small clumps (<5 mm²) and split

into two polyHEMA-coated 100-mm petri dishes. The floating clumps were cultured in RIM supplemented with IGF1 (ThermoFisher Scientific) and 1 mM taurine (Sigma), with 55 μ M 2-ME freshly added. From D38 and onward, 10% fetal bovine serum was added to RIM supplemented with 20 ng/ml IGF-1, and 1 mM taurine. 1 μ M 9-*cis* retinal was freshly supplemented to the cultures during media change from D63 to D91. From D91 till the end of differentiation, the concentration of 9-*cis* retinal was reduced to 0.5 μ M and B27 without Vitamin A was replaced by N2. Once scraped, media were half changed every 2-3 days, with IGF1, taurine and 9-*cis* retinal freshly added to the media under dim light environment.

Dissociation of mouse retinal organoids into single cells

Mouse retinal organoids were transferred into a 15 ml centrifuge tube using wide-bored transfer pipets and washed one time with 10 ml 1x PBS (ThermoFisher Scientific). Prewarmed 1 ml 0.25% trypsin-EDTA was then added, and the tube was incubated at 37°C for 10 minutes, with pipetting up and down for 10 times using P1000 pipetman at 5- and 10-minute incubation. 10 ml retinal maturation media (DMEM/F12 with GlutaMAX, 1x PS, 1x N2 supplement, 1 mM taurine, 500 nM 9-*cis* retinal, 1x NEAA, 1x B27 supplement without Vitamin A, 2%(v/v) FBS) was added to the tube. The tube was inverted several times before centrifugation at 200g for 5 minutes. After removal of supernatant, the cell pellet was resuspended in 1 ml retinal maturation media and filtered through 40- μ m cell strainer (BD Bioscience) before proceeding to subsequent analyses.

Immunoblot analysis

At least 3 organoids in each batch were homogenized in 100 μ l of RIPA buffer (Sigma) supplemented with 1x protease inhibitors (Roche) and 1x phosphatase inhibitor (Roche). The lysate was agitated at 4°C for half an hour, before centrifugation at 12,000g for 10 minutes at

4°C. The supernatant was either stored at -80 °C until use or quantified by Pierce bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific). Approximately 20 µg protein was diluted 4:1 in reducing 4x Laemmli buffer (Biorad) and boiled for 10 minutes. The samples were separated at 150-180 V for 1 hour on 4-15% precast polyacrylamide gel (Biorad) and transferred to polyvinylidene fluoride (PVDF) membranes using a TransBlot® Turbo™ Transfer System (Biorad). After blocking in 5% milk or 5% bovine serum albumin (BSA) for 1 hour at room temperature, the blots were incubated in antibody cocktails (Table S1) overnight in 1% milk or BSA in 1X TBS-T at 4 °C overnight with gentle agitation. Membranes were subsequently washed in 1X TBS-T for 3 times, 10 minutes each, and incubated in 1X TBS-T with horseradish peroxidase-conjugated secondary antibodies (1:5,000) for 1 hour at room temperature, followed by another three 10-minute wash. Before imaging, the membranes were exposed to SuperSignal® West Pico enhanced chemiluminescence (ECL) solution (ThermoFisher Scientific) for 5 minutes, and chemiluminescence was captured using a Bio-Rad ChemiDoc™ touch (Bio-Rad).

Chymotrypsin-like proteasome activity assay

The chymotrypsin-like protease activity associated with the proteasome complex in organoids or mouse retina was quantified using the Proteasome 20S Activity Assay Kit (Sigma) following manufacturer's protocol. In short, at least 3 retinal organoids or 1 mouse retina were homogenized in 55 µl PBS mixed with 55 µl reconstituted Proteasome Assay Loading Solution and incubated on ice for 30 minutes. After centrifuging at 10,000 g for 10 minutes at 4 °C, 10 µl supernatant was taken for BCA assay to determine the protein amount and the remaining 100 µl was transferred to one well of black/clear 96-well plate for incubation at 37 °C. Protease activity of individual samples was measured by the fluorescence intensity ($\lambda_{ex} = 480\text{--}500\text{ nm}$ / $\lambda_{em} =$

520–530 nm) normalized to the protein amount.

Transmission electron microscopy

Retinal organoids were processed for transmission electron microscopy (TEM) analysis as previously described (33). Briefly, the organoids were fixed in 4% formaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 (Tousimis) for 2 hours at room temperature, followed by 3 washes in cacodylate buffer before further fixation in osmium tetroxide (1% v/v in 0.1 M cacodylate buffer; Electron Microscopy Sciences) for 1 hour at room temperature. The organoids were then washed in the same buffer for three times, followed by 1 wash in acetate buffer (0.1 M, pH 4.2), and *en-bloc* staining in uranyl acetate (0.5% w/v; Electron Microscopy Sciences) in acetate buffer for 1 hour at room temperature. The samples were dehydrated in a series of ethanol solutions (35%, 50%, 75%, 95%, and 100%) and then by propylene oxide. The samples were subsequently infiltrated in a mixture of propylene oxide and epoxy resin (1:1, v/v) overnight, embedded in a flat mold with pure epoxy resin, and cured at 55 °C for 48 hours. 70-80 nm sections were made with an ultramicrotome (UC 7) and diamond knife (Diatome), attached on a 200-mesh copper grid, and counter-stained in aqueous solution of uranyl acetate (0.5% w/v) and then lead citrate solutions. The thin sections were stabilized by carbon evaporation before the EM examination. The digital images were taken using a digital camera equipped with an electron microscope (H7650) (AMT).

Flow cytometry

After dissociating retinal organoids, the cells were resuspended in DPBS (ThermoFisher Scientific) containing 1 mM EDTA (Millipore) and filtered through a 40- μ m cell strainer. 4',6-diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific) was added to the samples before being analyzed by FACS Aria II (BD Bioscience). Cell viability was evaluated by integrity (gated

by DAPI), size (gated by forward scatter, FSC) and granularity (gated by side scatter, SSC). WT retinal organoids without GFP marker on the same differentiation day were used to set the gating for GFP+ cells.

RNA extraction and library preparation

Total RNA was purified from homogenized retinal organoids using TriPure isolation reagent (Roche). Quality of isolated RNAs was assessed using Bioanalyzer RNA 6000 nano assays (Agilent) and high-quality total RNA (RNA integrity number ≥ 7.5) were used for construction of mRNA sequencing library. 100 ng total RNA were used to construct the strand-specific libraries using TruSeq RNA Sample Prep Kit-v2 (Illumina).

RNA-seq data analysis

RNA sequencing was performed as described (116). Paired-end 125-bp reads were generated using Illumina sequencing. Reads were quality checked and mapped to the reference transcriptome using Kallisto. Alignments were imported into R using tximport for downstream analyses. The edgeR and limma pipeline were employed for differential expression analysis, while pathway annotation was performed using ClueGO (117). Protein interaction data was obtained from STRING (v11.5) with evidence cut off of 700, via the R package STRINGdb (118). Network analysis was performed using the *igraph* package [<https://igraph.org>] and genes were mapped to pathways using gProfileR (119). Proteostasis network genes were manually collected by pooling KEGG and Reactome pathways with keywords from (62) and (63), and the proteosome map was adapted from KEGG (hsa03050). Gene set enrichment analysis was done using the R package fgsea. All other plotting and analyses, unless otherwise mentioned, were performed using tidyverse and base R packages.

Immunohistochemistry

Mouse and human organoids were fixed in 4% PFA (Electron Microscopy Sciences) for 1 hour at room temperature, washed 1 time and cryoprotected in 15% sucrose for at least 2 hours at room temperature, followed by 30% sucrose at 4°C overnight. The next day, organoids were embedded in Shandon M-1 Embedding Matrix (ThermoFisher Scientific). The blocks were sectioned at 10 µm thickness and incubated at room temperature for at least 1 hour, before immunostaining or storage at -80 °C. After incubating in blocking solution (5% donkey serum in PBS) for 1 hour at room temperature, the sections were supplied with diluted primary antibodies (Table S1) at 4°C overnight. After three 10-min washes in PBS, Species-specific secondary antibodies conjugated with Alexa Fluor 488, 568 or 637, together with DAPI, were diluted in blocking solution (1:500; ThermoFisher Scientific) and incubated with the sections for 1 hour at room temperature. After washing in PBS for three times, 10 minutes each, the sections were mounted for imaging.

For mouse retinal sections, *rd16* mice of both sexes were injected at postnatal (P) day 4 and recovered at P21 after euthanasia using CO₂ atmosphere. Eyes were denucleated before being pierced in the center of the cornea using a 26-gauge needle. Eyecups were then incubated for 15 min in 4% paraformaldehyde (PFA). The cornea and lens were then dissected, and the eyecups were placed in 4% PFA for 15 min at room temperature (RT) before proceeding to cryoprotection in 20% and 30% sucrose-PBS at 4C for 1 hour and overnight, respectively. Eyecups were then quickly frozen in Shandon™ M-1 Embedding Matrix (Thermo Fisher Scientific) and cut at 12µm. Retinal sections were washed twice in PBS then blocked in PBS containing 5% Donkey serum and 0.3% Triton X-100 (PBST) for 1 hour at room temperature. Slides were incubated overnight at 4°C with primary antibody diluted in PBST at an appropriate concentration (Table S1). Sections were then washed 3 times with PBS and incubated with

secondary antibody and 1 $\mu\text{g/ml}$ 4,6-diamidino-2-phenylindole (DAPI) for 1 hour at room temperature. After 3 washes in PBS, the sections were mounted in Fluoromount-G (SouthernBiotech).

Image acquisition and analysis

Brightfield images were taken using an EVOS XL Core Cell Imaging System (ThermoFisher). Fluorescence images were acquired with LSM-880 confocal microscope (Zeiss) with Zen software. FIJI and Photoshop CC 2019 software were used for images export, analyzing and processing. Rhodopsin and S-opsin fluorescent intensity of organoid sections were quantified with FIJI using the maximum intensity projections of z-stack images. Multi-channel RGB (red, green, blue) images were separated into 8-bit grayscale images and regions of interest were identified by applying the “Moment” threshold algorithm of FIJI. The same threshold algorithm was used for all images. Area, raw and integrated fluorescence intensity in each image were then quantified with Fiji and plotted using RStudio version 1.1.463.





Fig. S1. Phenotypes of retinal organoids differentiated from induced pluripotent stem cells of *Nrl-GFP rd16* mice.

(A) Deletion of myosin tail domain in *rd16* mice compared to the wild type (WT) ones. (B) Morphology of iPSC colonies, (C) proliferation rate of iPSCs, and (D) photoreceptor primary cilium of organoids were compared between WT and *rd16*. (E) Timeline of the key differentiation events in mouse organoids and primary screens. Images were representative of at least 3 independent experiments, each of which had at least 3 organoids.


A

Subjects	Phenotype	Allele 1	Allele 2
Control	Unaffected	Wild type	c.5668G>T p.G1890X
LCA-1	CEP290-LCA	IVS26+1655A>G p.C998X	c.5668G>T p.G1890X
LCA-2	CEP290-LCA	IVS26+1655A>G p.C998X	c.5668G>T p.G1890X

B



C



D




Fig. S2. Genotype and phenotype of the *LCA10* family in this study.

(A) Genotypes of the subjects including a heterozygous but phenotypically normal control and two *LCA10* patients. (B) Location of the stop codons caused by point mutations in *LCA10* patients. (C) Western blot analysis of CEP290 in day (D) 200 control and patient retinal organoids. Images were representative of at least 3 independent experiments, each of which had at least 3 organoids. GAPDH was used as a loading control. (D) Immunostaining of rhodopsin (green) and ARL13B (red) in the left panel as well as rhodopsin (magenta), S-opsin (red) and L/M-opsin (green) in the right panel. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least 3 independent experiments, each of which had at least 3 organoids.




Fig. S3. Immunostaining of reserpine (RSP)-treated LCA-1 organoids.

(A) Rod cell marker rhodopsin (RHO, green) and ciliary marker ARL13B (red) were shown in LCA1 organoids treated with 30 μ M RSP at differentiation day (D) 125 (upper) and with 10 μ M RSP at D150 (lower). (B) Immunostaining of structural or cell type-specific markers including those for ribbon synapses (BASSON, red), presynaptic vesicles (SYNAPTOPHYSIN, green), bipolar cells (CHX10, green; PKCa, red), Müller glia (CRALBP, green; GFAP, red). Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least 3 independent experiments, each of which had at least 3 organoids.





Fig. S4. Transmission electron microscopy analyses of control, untreated and treated patient organoids.

(A) Morphology of photoreceptor primary cilium. **(B)** Stacks of disc-like structures observed in treated patient organoids. Arrowheads indicate relevant structures.




Fig. S5. Altered expression of retinal pathway genes by reserpine treatment.

(A) Timeline of treatment and sample harvest. (B) Different retinal cell types appeared to respond uniquely to reserpine. (C) Phototransduction genes were globally downregulated except for specific genes like OPN3. (D) Genes associated with photoreceptor cilia showed mixed trends. (E) Functional clustering of differentially expressed genes show activity in cell survival pathways. (F) TP53 gene expression change with reserpine treatment. (G) Heatmap of p53 signaling pathway (combination of KEGG, Reactome and Hallmark genes). (H) Transcriptional response of TSC1 and TSC2 genes show reduced expression after reserpine treatment. (I) Expression of mTOR pathway genes upon reserpine treatment.




Fig. S6. Effect of autophagy modulators on LCA-1 organoids.

(A) Schematic diagram of autophagy with annotation of the drug effect of autophagy inhibitors.

(B) Immunostaining of rhodopsin (green), S-opsin (red), and L/M-opsin (magenta) was used to evaluate the effect of chloroquine, hydroxychloroquine, and ROC-325. (C) Western blot and quantification of p62, LC3-II and LC3-II/LC3-I ratio upon bafilomycin A1 (BafA1) treatment.

The drug vehicle dimethylsulfoxide (DMSO) was added to the cultures in the untreated group at the same volume as the drug. b-Actin was used as the loading control. The histograms summarize data in at least 3 batches of experiments, each of which contained at least 3 retinal organoids per group. Each dot in the histogram shows data in one batch of experiment and are presented as mean \pm standard error. *, $p < 0.05$. (D) Treatment timeline (left) and outcome of Tubastatin A treatment (right) as shown by immunostaining of rhodopsin (green) and S-opsin (red). In all images, nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least 2 independent experiments, each of which had at least 3 organoids.








Fig. S7. Intravitreal injection of reserpine (RSP) to *rd16* mice.

(A) Evaluation of the impact of different injection schemes on outer nuclear layer (ONL) thickness of central and peripheral retina. Each dot in the bee swamp plot indicates the ONL thickness of one retina from one mouse. The shape of the plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals standard deviation. (B) Immunostaining of phototransduction protein rhodopsin (RHO, magenta) and PDE6 β (red). (C) Retinal structures and cell types shown by synaptophysin for presynaptic vesicles (magenta, top panel), bassoon for ribbon synapses (red, top panel), PKCa for bipolar cells (red, middle panel), Calretinin for amacrine cells (magenta, middle panel), GFAP for cellular stress and Müller glia (red, bottom panel). Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least 3 mice, each of which was from a different litter.

Supplemental Table 1. Antibody information

Antibody	Vendor	Catalog #	Host	Dilution	
				IHC*	IB^
Rhodopsin (RHO)	Gift of Dr. Robert Molday, Univ British Columbia		Mouse	1:500	1:1000
S-opsin	Santa Cruz	sc-14363	Goat	1:500	
Polyglutamylation Modification (GT335)	AdipoGen	AG-20B-0020	Mouse	1:250	
Rootletin	Chicken	Custom	Chicken	1:250	
ADP-ribosylation factor-like protein 13B (Arl13b)	Proteintech	17711-1-AP	Rabbit	1:500	
L/M-opsin (OPN1LMW)	Millipore	AB5405	Rabbit	1:500	
Centrosomal protein 290 (CEP290)	Bethyl laboratories	A301-659A	Rabbit		1:500
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	Millipore/Sigma	G8795	Mouse		1:1000

*IHC, immunohistochemistry

^IB, immunoblotting